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Abstract 
Antiretroviral treatments (ART) have dramatically reduced HIV infection mortality, 
transforming HIV infection into a chronic disease requiring life-long treatment. Sadly, 
treatment is associated with a number of metabolic, cardiovascular, osteoarticular, renal 
and central nervous system toxicities. Moreover, Chronic HIV infection is associated with 
low-level inflammation and increased risk of chronic diseases and mortality. As a result, 
long-term treated patients may present with increased risk of cardiovascular and 
cerebrovascular disease, lypodystrophy, early diabetes, kidney failure, osteoporosis and 
cognitive impairment. These toxicities imitate age-associated comorbidities. Indeed, long-
term HIV infection and ART use appear to predispose patients to premature aging and 
accelerate the risk of these comorbidities. 
In the general population the risk of cardiovascular and metabolic conditions can be 
reduced by lifestyle interventions, such as dietary adjustments, exercise, smoking 
cessation, and by pharmacological approaches. Similar general and pharmacological 
measures are also indicated in HIV persons and anti-hypertensive and lipid-lowering drugs 
are frequently used in association with ART. 
Among lifestyle measures, exercise, involving both aerobic and strength training, is 
associated with reduction of cardiovascular events in the normal population. In older 
persons regular physical activity has been shown to lower overall mortality, risk of 
coronary heart disease, colon cancer, diabetes, obesity and of developing high blood 
pressure; to improve mood and relief of symptoms of depression, quality of life and 
functioning. In addition to prevent these morbidities, physical activity is also effective in 
treating cardiovascular disease, high blood pressure, high cholesterol, chronic lung 
disease, diabetes, obesity, and osteoarthritis. 
There is evidence that exercise is also useful in people with HIV infection. Although 
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studies have differed for design (controlled vs. single arm), sample size (up to 20 subjects 
per group), type of activity (aerobic vs. strength vs. both), training frequency (2-3 session a 
week), duration (weeks-few months), most have shown, with aerobic exercise, a reduction 
of abdominal and total body fat, total cholesterol, triglycerides, BMI, hip circumference, and 
increases in HDL. In contrast, strength exercise, either alone, or in association with 
aerobic exercise, seems to be associated with increased fat free mass and of muscle 
strength. 
The general objective was to study the effects at 12 weeks of supervised moderate 
aerobic exercise (walking) with/without strength training in patients with HIV infection on 
chronic ART. Ultimately, we aim to validate an exercise approach to propose for 
prevention and treatment of ART- 
 
For this reason a pilot study enrolling cART-treated, sedentary persons with metabolic 
complications in a 12-week protocol, consisting of three sessions per week of 60 min brisk 
walking with (strength walk group) or without (walk group) 30 min circuit-training, was 
proposes. 
 
Assessments at baseline and week 12 (W12) included body morphometrics and total body 
dual-energy X-ray absorptiometry; lipid and glucose blood profile; plasma level of high 
sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), D-dimer, interleukin-18 (IL-18), 
soluble CD14 and myostatin, and CD38 and HLA-DR expression on CD4+ and CD8+ T-
cells were done. 
 
Forty-nine patients were enrolled and 35 (71%) completed the program: 21 in the walk and 
14 in the strength-walk group. Median adherence to the training sessions was 67%. At 
W12, significant improvements were observed of body mass index, waist and hip 
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circumference, and total and LDL cholesterol, with no change differences between training 
groups. Overall, significant reductions were observed in hsCRP, IL-6, D-dimer, IL-18 and 
myostatin level, and of CD8+/CD38+/HLA-DR+ cell frequencies. HsCRP and 
CD8+/CD38+/HLA-DR+ frequency decreased significantly in both training groups; IL-6 and 
D-dimer in the walk group only and myostatin in the strength-walk group only. 
 
Brisk walking, with or without strength exercise, can improve lipid profile and inflammatory 
markers in chronic HIV infection. 
 
Keywords. Immune activation, inflammatory markers, exercise, physical activity, cART, 
cholesterol  
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PART ONE 
General Introduction 
Human Immunodeficiency Virus (HIV) 
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that 
causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which 
progressive failure of the immune system allows life-threatening opportunistic infections 
and cancers to thrive. Without treatment, average survival time after infection with HIV is 
estimated to be 9 to 11 years, depending on the HIV subtype. Infection with HIV occurs by 
the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily 
fluids, HIV is present as both free virus particles and virus within infected immune cells. 
HIV infects vital cells in the human immune system such as helper T cells (specifically 
CD4+ T cells), macrophages, and dendritic cells.  
 
 
 
Figure 1. Scanning electron micrograph of HIV-1 budding, in green, from cultured 
lymphocyte (Centres for Disease Control and Prevention's Public Health, modified) 
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HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, 
including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and 
killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. 
When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, 
and the body becomes progressively more susceptible to opportunistic infections. 
 
Virology 
HIV is the cause of the spectrum of disease known as HIV/AIDS. HIV is a retrovirus that 
primarily infects components of the human immune system such as CD4+ T cells, 
macrophages and dendritic cells. It directly and indirectly destroys CD4+ T cells. 
HIV is a member of the genus Lentivirus, part of the family Retroviridae. Lentiviruses share 
many morphological and biological characteristics. Many species of mammals are infected 
by lentiviruses, which are characteristically responsible for long-duration illnesses with a 
long incubation period. Lentiviruses are transmitted as single-stranded, positive-sense, 
enveloped RNA viruses. Upon entry into the target cell, the viral RNA genome is converted 
(reverse transcribed) into double-stranded DNA by a virally encoded reverse transcriptase 
that is transported along with the viral genome in the virus particle. The resulting viral DNA 
is then imported into the cell nucleus and integrated into the cellular DNA by a virally 
encoded integrase and host co-factors. Once integrated, the virus may become latent, 
allowing the virus and its host cell to avoid detection by the immune system. Alternatively, 
the virus may be transcribed, producing new RNA genomes and viral proteins that are 
packaged and released from the cell as new virus particles that begin the replication cycle 
anew. 
Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that was 
originally discovered (and initially referred to also as LAV or HTLV-III). It is more virulent, 
more infective, and is the cause of the majority of HIV infections globally. The lower 
 infectivity of HIV-2 as compared with HIV
be infected per exposure. Because of its relatively poor capacity for transmission, HIV
largely confined to West Africa.
 
Pathophysiology 
After the virus enters the body there is a period of rapid viral replication, leading to an 
abundance of virus in the peripheral blood. During primary infection, the level of HIV may 
reach several million-virus particles per milli
Figure 2. A generalized graph of the r
CD4+ counts over the average co
CD4+ T cell count (cells per µL)
HIV RNA copies per mL of plasma
 
This response is accompanied by a marked drop in the numbers of circulating CD4+ T 
cells. This acute viremia is associated in virtually all people with the activation of CD8+ T 
cells, which kill HIV-infected cells, and subsequently with antibody production
seroconversion. The CD8+ T cell response is thought to be important in controlling virus 
-1 implies that fewer people exposed to HIV
 
litre of blood. 
elationship between HIV copies, 
urse of untreated HIV infection.
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levels, which peak and then decline, as the CD4+ T cell counts rebound. A good CD8+ T 
cell response has been linked to slower disease progression and a better prognosis, 
though it does not eliminate the virus. 
The pathophysiology of AIDS is complex. Ultimately, HIV causes AIDS by depleting CD4+ 
T helper lymphocytes. This weakens the immune system and allows opportunistic 
infections. T lymphocytes are essential to the immune response and without them; the 
body cannot fight infections or kill cancerous cells. The mechanism of CD4+T cell 
depletion differs in the acute and chronic phases. 
During the acute phase, HIV-induced cell lysis and killing of infected cells by cytotoxic T 
cells accounts for CD4+ T cell depletion, although apoptosis may also be a factor. During 
the chronic phase, the consequences of generalized immune activation coupled with the 
gradual loss of the ability of the immune system to generate new T cells appear to account 
for the slow decline in CD4+ T cell numbers. 
Although the symptoms of immune deficiency characteristic of AIDS do not appear for 
years after a person is infected, the bulk of CD4+ T cell loss occurs during the first weeks 
of infection, especially in the intestinal mucosa, which harbours the majority of the 
lymphocytes found in the body. The reason for the preferential loss of mucosal CD4+ T 
cells is that a majority of mucosal CD4+ T cells express the CCR5 co-receptor, whereas a 
small fraction of CD4+ T cells in the bloodstream do so. 
HIV seeks out and destroys CCR5 expressing CD4+ cells during acute infection. A 
vigorous immune response eventually controls the infection and initiates the clinically 
latent phase. However, CD4+ T cells in mucosal tissues remain depleted throughout the 
infection, although enough remain to initially ward off life-threatening infections. 
Continuous HIV replication results in a state of generalized immune activation persisting 
throughout the chronic phase. Immune activation, which is reflected by the increased 
activation state of immune cells and release of pro-inflammatory cytokines, results from 
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the activity of several HIV gene products and the immune response to ongoing HIV 
replication. Another cause is the breakdown of the immune surveillance system of the 
mucosal barrier caused by the depletion of mucosal CD4+ T cells during the acute phase 
of disease. 
This results in the systemic exposure of the immune system to microbial components of 
the gut’s normal flora, which in a healthy person is kept in check by the mucosal immune 
system. The activation and proliferation of T cells that results from immune activation 
provides fresh targets for HIV infection. However, direct killing by HIV alone cannot 
account for the observed depletion of CD4+ T cells since only 0.01–0.10% of CD4+ T cells 
in the blood are infected. 
A major cause of CD4+ T cell loss appears to result from their heightened susceptibility to 
apoptosis when the immune system remains activated. Although new T cells are 
continuously produced by the thymus to replace the ones lost, the regenerative capacity of 
the thymus is slowly destroyed by direct infection of its thymocytes by HIV. Eventually, the 
minimal number of CD4+ T cells necessary to maintain a sufficient immune response is 
lost, leading to AIDS. 
 
 Sings and symptoms  
Acute infection 
Acute HIV infection, primary HIV infection or acute sero-conversion syndrome is the 
second stage of HIV infection. It occurs after the incubation stage, before the latency stage 
and the potential AIDS succeeding the latency stage. 
During this period (usually days to weeks post-exposure) many individuals develop an 
influenza or mononucleosis-like illness called acute HIV infection, the most common 
symptoms of which may include fever, lymphadenopathy, pharyngitis, rash, myalgia, 
malaise, mouth and oesophageal sores, and may also include, but less commonly, 
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headache, nausea and vomiting, enlarged liver/spleen, weight loss, thrush, and 
neurological symptoms. Infected individuals may experience all, some, or none of these 
symptoms. The duration of symptoms varies, averaging 28 days and usually lasts at least 
a week. 
Because of the nonspecific nature of these symptoms, they are often not recognized as 
signs of HIV infection. Even if patients go to their doctors or a hospital, they will often be 
misdiagnosed as having one of the more common infectious diseases with the same 
symptoms. As a consequence, these primary symptoms are not used to diagnose HIV 
infection, as they do not develop in all cases and because other more common diseases 
cause many. However, recognizing the syndrome can be important because the patient is 
much more infectious during this period. 
 
Latency 
A strong immune defence reduces the number of viral particles in the blood stream, 
marking the start of secondary or chronic HIV infection. The secondary stage of HIV 
infection can vary between two weeks and 20 years. During this phase of infection, HIV is 
active within lymph nodes, which typically become persistently swollen, in response to 
large amounts of virus that become trapped in the follicular dendritic cells (FDC) network. 
The surrounding tissues that are rich in CD4+ T cells may also become infected, and viral 
particles accumulate both in infected cells and as free virus. Individuals who are in this 
phase are still infectious. During this time, CD4+ CD45RO+ T cells carry most of the 
proviral load. A small percentage of HIV-1 infected individuals retain high levels of CD4+ 
T-cells without antiretroviral therapy. However, most have detectable viral load and will 
eventually progress to AIDS without treatment. These individuals are classified as HIV 
controllers or long-term nonprogressors (LTNP). People who maintain CD4+ T cell counts 
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and also have low or clinically undetectable viral load without anti-retroviral treatment are 
known as elite controllers or elite suppressors (ES). 
 
AIDS 
The symptoms of AIDS are primarily the result of conditions that do not normally develop 
in individuals with healthy immune systems. Most of these conditions are opportunistic 
infections caused by bacteria, viruses, fungi and parasites that are normally controlled by 
the elements of the immune system that HIV damages. These infections affect nearly 
every organ system. 
People with AIDS also have an increased risk of developing various cancers such as 
Kaposi's sarcoma, cervical cancer and cancers of the immune system known as 
lymphomas. Additionally, people with AIDS often have systemic symptoms of infection like 
fevers, sweats (particularly at night), swollen glands, chills, weakness, and weight loss. 
The specific opportunistic infections that AIDS patients develop depend in part on the 
prevalence of these infections in the geographic area in which the patient lives. 
 
History of HIV/AIDS 
AIDS was first clinically observed in 1981 in the United States. The initial cases were a 
cluster of injecting drug users and homosexual men with no known cause of impaired 
immunity who showed symptoms of Pneumocystis carinii pneumonia (PCP), a rare 
opportunistic infection that was known to occur in people with very compromised immune 
systems. Soon thereafter, an unexpected number of homosexual men developed a 
previously rare skin cancer called Kaposi's sarcoma (KS). Many more cases of PCP and 
KS emerged, alerting U.S. Centers for Disease Control and Prevention (CDC) and a CDC 
task force was formed to monitor the outbreak. 
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In the early days, the CDC did not have an official name for the disease, often referring to 
it by way of the diseases that were associated with it, for example, lymphadenopathy, the 
disease after which the discoverers of HIV originally named the virus. They also used 
Kaposi's sarcoma and Opportunistic Infections, the name by which a task force had been 
set up in 1981. At one point, the CDC coined the phrase "the 4H disease", since the 
syndrome seemed to affect Haitians, homosexuals, haemophiliacs, and heroin users. In 
the general press, the term "GRID", which stood for gay-related immune deficiency, had 
been coined. However, after determining that AIDS was not isolated to the gay community, 
it was realized that the term GRID was misleading and the term AIDS was introduced at a 
meeting in July 1982. By September 1982 the CDC started referring to the disease as 
AIDS. 
In 1983, two separate research groups led by Robert Gallo and Luc Montagnier 
independently declared that a novel retrovirus may have been infecting people with AIDS, 
and published their findings in the same issue of the journal Science. Gallo claimed that a 
virus his group had isolated from a person with AIDS was strikingly similar in shape to 
other human T-lymphotropic viruses (HTLVs) his group had been the first to isolate. 
Gallo's group called their newly isolated virus HTLV-III. At the same time, Montagnier's 
group isolated a virus from a person presenting with swelling of the lymph nodes of the 
neck and physical weakness, two characteristic symptoms of AIDS. Contradicting the 
report from Gallo's group, Montagnier and his colleagues showed that core proteins of this 
virus were immunologically different from those of HTLV-I. Montagnier's group named their 
isolated virus lymphadenopathy-associated virus (LAV). As these two viruses turned out to 
be the same, in 1986, LAV and HTLV-III were renamed HIV. 
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Origin of HIV 
Both HIV-1 and HIV-2 are believed to have originated in non-human primates in West-
central Africa and were transferred to humans in the early 20th century. HIV-1 appears to 
have originated in southern Cameroon through the evolution of SIV (cpz), a simian 
immunodeficiency virus (SIV) that infects wild chimpanzees (HIV-1 descends from the 
SIVcpz endemic in the chimpanzee subspecies Pan troglodytes troglodytes).  
 
Figure 3. Origins of human AIDS viruses, old world monkeys are naturally infected with 
more than 40 different lentiviruses, termed simian immunodeficiency viruses, SIVs, with a 
suffix to denote their primate species of origin. Several of these SIVs have crossed the 
species barrier to great apes and humans, generating new pathogens. Known examples of 
cross-species transmissions, as well as the resulting viruses, are highlighted in red. 
(From Sharp & Hahn, 2011, modified) 
 
The closest relative of HIV-2 is SIV (smm), a virus of the sooty mangabey (Cercocebus 
atys atys), an Old World monkey living in coastal West Africa (from southern Senegal to 
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western Côte d'Ivoire). New World monkeys such as the owl monkey are resistant to HIV-1 
infection, possibly because of a genomic fusion of two viral resistance genes. HIV-1 is 
thought to have jumped the species barrier on at least three separate occasions, giving 
rise to the three groups of the virus, M, N, and O.There is evidence that humans who 
participate in bushmeat activities, either as hunters or as bushmeat vendors, commonly 
acquire SIV. However, SIV is a weak virus which is typically suppressed by the human 
immune system within weeks of infection. It is thought that several transmissions of the 
virus from individual to individual in quick succession are necessary to allow it enough time 
to mutate into HIV. Furthermore, due to its relatively low person-to-person transmission 
rate, SIV can only spread throughout the population in the presence of one or more high-
risk transmission channels, which are thought to have been absent in Africa before the 
20th century. 
Specific proposed high-risk transmission channels, allowing the virus to adapt to humans 
and spread throughout the society, depend on the proposed timing of the animal-to-human 
crossing. Genetic studies of the virus suggest that the most recent common ancestor of 
the HIV-1 M group dates back to circa 1910. Proponents of this dating link the HIV 
epidemic with the emergence of colonialism and growth of large colonial African cities, 
leading to social changes, including a higher degree of sexual promiscuity, the spread of 
prostitution, and the accompanying high frequency of genital ulcer diseases (such as 
syphilis) in nascent colonial cities. While transmission rates of HIV during vaginal 
intercourse are low under regular circumstances, they are increased many fold if one of 
the partners suffers from a sexually transmitted infection causing genital ulcers. Early 
1900s colonial cities were notable due to their high prevalence of prostitution and genital 
ulcers, to the degree that, as of 1928, as many as 45% of female residents of eastern 
Kinshasa were thought to have been prostitutes, and, as of 1933, around 15% of all 
residents of the same city had syphilis. 
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An alternative view holds that unsafe medical practices in Africa after World War II, such 
as unsterile reuse of single use syringes during mass vaccination, antibiotic and anti-
malaria treatment campaigns, were the initial vector that allowed the virus to adapt to 
humans and spread. 
The earliest well documented case of HIV in a human date back to 1959 in the Congo. 
The virus may have been present in the United States as early as 1966, but the vast 
majority of infections occurring outside sub-Saharan Africa (including the U.S.) can be 
traced back to a single unknown individual who became infected with HIV in Haiti and then 
brought the infection to the United States some time around 1969. The epidemic then 
rapidly spread among high-risk groups (initially, sexually promiscuous men who have sex 
with men). By 1978, the prevalence of HIV-1 among homosexual male residents of New 
York and San Francisco was estimated at 5%, suggesting that several thousand 
individuals in the country had been infected. 
 
Transmission 
Only certain fluids—blood, semen (cum), pre-seminal fluid (pre-cum), rectal fluids, vaginal 
fluids, and breast milk—from an HIV-infected person can transmit HIV. These fluids must 
come in contact with a mucous membrane or damaged tissue or be directly injected into 
the bloodstream (from a needle or syringe) for transmission to possibly occur. Mucous 
membranes can be found inside the rectum, the vagina, the opening of the penis, and the 
mouth. 
HIV does not survive long outside the human body (such as on surfaces), and it cannot 
reproduce. It is not spread by: air or water, insects, including mosquitoes or ticks, saliva, 
tears, or sweat.  
There are cases where HIV was transmitted orally, so it's not completely without risk to 
have HIV-infected semen, vaginal fluid or blood in mouth. However, oral sex is considered 
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a low risk practice. The virus can't survive well in the mouth (in semen, vaginal fluid or 
blood), so the risk of HIV transmission through the throat, gums, and oral membranes is 
lower than through vaginal or anal membranes. 
There is no documented case of HIV being transmitted by spitting, casual contact like 
shaking hands or sharing dishes, closed-mouth or “social” kissing, toilet seats. 
Having an undetectable viral load greatly lowers the chance that a person living with HIV 
can transmit the virus to a partner, but there is still some risk. “Viral load” refers to the 
amount of HIV in an infected person’s blood. An “undetectable viral load” is when the 
amount of HIV in a person’s blood is so low that it can’t be measured. Antiretroviral 
therapy (ART) reduces a person’s viral load, ideally to an undetectable level, when taken 
consistently and correctly. However, a person with HIV can still potentially transmit HIV to 
a partner even if they have an undetectable viral load, because: 
HIV may still be found in a person’s genital fluids (e.g., semen, vaginal fluids). The viral 
load test only measures virus in a person’s blood. 
A person’s viral load may go up between tests. When this happens, they may be more 
likely to transmit HIV to partners. 
Sexually transmitted diseases (STDs) increase viral load in a person’s genital fluids. 
 
Sexual intercourse 
Anal and vaginal intercourses are high-risk activities. In the penis, vagina and anus, HIV 
may enter through cuts and sores (many of which would be very small and hard to notice), 
or directly through the mucus membranes. 
 
Sharing injection needles or works  
Sharing needles or other materials used for injecting are considered a high-risk practice. 
Injection needles can pass blood directly from one person to another if you share them. If 
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a person with HIV injects with a needle then shares it with another person, the second 
person is at very high risk for getting HIV. 
 
Mother-to-child 
Mother to child transmission is now rare in the US and other developed countries because 
pregnant women who are HIV-positive are normally given medications to prevent the fetus 
from getting infected. However, it is possible for an HIV-infected mother to pass the virus 
directly before or during birth, or through breast milk. Breast milk contains HIV, and while 
small amounts of breast milk do not pose significant threat of infection to adults, it is a risk 
for infants. 
 
Prevention 
Sexual contact 
Consistent condom use reduces the risk of HIV transmission by approximately 80% over 
the long term. When a couple in which one person is infected uses condoms consistently, 
the rate of HIV infection is less than 1% per year. There is some evidence to suggest that 
female condoms may provide an equivalent level of protection. Application of a vaginal gel 
containing tenofovir (a reverse transcriptase inhibitor) immediately before sex seems to 
reduce infection rates by approximately 40% among African women. By contrast, use of 
the spermicide nonoxynol-9 may increase the risk of transmission due to its tendency to 
cause vaginal and rectal irritation. Circumcision in Sub-Saharan Africa "reduces the 
acquisition of HIV by heterosexual men by between 38% and 66% over 24 months". 
Based on these studies, the World Health Organization and UNAIDS both recommended 
male circumcision as a method of preventing female-to-male HIV transmission in 2007. 
Whether it protects against male-to-female transmission is disputed and whether it is of 
benefit in developed countries and among men who have sex with men is undetermined. 
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The International Antiviral Society; however, does recommend for all sexually active 
heterosexual males and that it be discussed as an option with men who have sex with 
men. Some experts fear that a lower perception of vulnerability among circumcised men 
may cause more sexual risk-taking behaviour, thus negating its preventive effects. 
Programs encouraging sexual abstinence do not appear to affect subsequent HIV risk. 
Evidence for a benefit from peer education is equally poor. Comprehensive sexual 
education provided at school may decrease high-risk behaviour. A substantial minority of 
young people continues to engage in high-risk practices despite knowing about HIV/AIDS, 
underestimating their own risk of becoming infected with HIV. Voluntary counselling and 
testing people for HIV does not affect risky behaviour in those who test negative but does 
increase condom use in those who test positive. It is not known whether treating other 
sexually transmitted infections is effective in preventing HIV. 
 
Pre-exposure 
Treating people with HIV whose CD4 count ≥ 350cells/µL with antiretrovirals protects 96% 
of their partners from infection. This is about a 10 to 20-fold reduction in transmission risk. 
Pre-exposure prophylaxis (PrEP) with a daily dose of the medications tenofovir, with or 
without emtricitabine, is effective in a number of groups including men who have sex with 
men, couples where one is HIV positive, and young heterosexuals in Africa. It may also be 
effective in intravenous drug users with a study finding a decrease in risk of 0.7 to 0.4 per 
100 person years. Universal precautions within the health care environment are believed 
to be effective in decreasing the risk of HIV. Intravenous drug use is an important risk 
factor and harm reduction strategies such as needle-exchange programmes and opioid 
substitution therapy appear effective in decreasing this risk. 
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Post-exposure  
A course of antiretrovirals administered within 48 to 72 hours after exposure to HIV-
positive blood or genital secretions is referred to as post-exposure prophylaxis (PEP). The 
use of the single agent zidovudine reduces the risk of a HIV infection five-fold following a 
needle-stick injury. As of 2013, the prevention regimen recommended in the United States 
consists of three medications—tenofovir, emtricitabine and raltegravir—as this may reduce 
the risk further. PEP treatment is recommended after a sexual assault when the 
perpetrator is known to be HIV positive, but is controversial when their HIV status is 
unknown. The duration of treatment is usually four weeks and is frequently associated with 
adverse effects-where zidovudine is used, about 70% of cases result in adverse effects 
such as nausea (24%), fatigue (22%), emotional distress (13%) and headaches (9%). 
 
Mother-to-child 
Programs to prevent the vertical transmission of HIV (from mothers to children) can reduce 
rates of transmission by 92–99%. This primarily involves the use of a combination of 
antiviral medications during pregnancy and after birth in the infant and potentially includes 
bottle feeding rather than breastfeeding. If replacement feeding is acceptable, feasible, 
affordable, sustainable, and safe, mothers should avoid breastfeeding their infants; 
however exclusive breastfeeding is recommended during the first months of life if this is 
not the case. If exclusive breastfeeding is carried out, the prevision of extended 
antiretroviral prophylaxis to the infant decreases the risk of transmission. 
 
Vaccination 
As of 2012 there is no effective vaccine for HIV or AIDS. A single trial of the vaccine RV 
144 published in 2009 found a partial reduction in the risk of transmission of roughly 30%, 
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stimulating some hope in the research community of developing a truly effective vaccine. 
Further trials of the RV 144 vaccine are ongoing. 
 
Diagnosis 
HIV tests are used to detect the presence of the human immunodeficiency virus (HIV), the 
virus that causes acquired immunodeficiency syndrome (AIDS), in serum, saliva, or urine. 
Such tests may detect antibodies, antigens, or RNA. 
Tests used for the diagnosis of HIV infection in a particular person require a high degree of 
both sensitivity and specificity. In the United States, this is achieved using an algorithm 
combining two tests for HIV antibodies. If antibodies are detected by an initial test based 
on the ELISA method, then a second test using the Western blot procedure determines 
the size of the antigens in the test kit binding to the antibodies. The combination of these 
two methods is highly accurate (see below). 
HIV antibody tests are specifically designed for routine diagnostic testing of adults; these 
tests are inexpensive and extremely accurate. 
 
Window period 
Antibody tests may give false negative (no antibodies were detected despite the presence 
of HIV) results during the window period, an interval of three weeks to six months between 
the time of HIV infection and the production of measurable antibodies to HIV 
seroconversion. Most people develop detectable antibodies approximately 30 days after 
infection, although some seroconvert later. The vast majority of people (97%) have 
detectable antibodies by three months after HIV infection; a six-month window is extremely 
rare with modern antibody testing. During the window period, an infected person can 
transmit HIV to others although their HIV infection may not be detectable with an antibody 
test. Antiretroviral therapy during the window period can delay the formation of antibodies 
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and extend the window period beyond 12 months. This was not the case with patients that 
underwent treatment with post-exposure prophylaxis (PEP). Those patients must take 
ELISA tests at various intervals after the usual 28-day course of treatment, sometimes 
extending outside of the conservative window period of 6 months. Antibody tests may also 
yield false negative results in patients with X-linked agammaglobulinemia; other diagnostic 
tests should be used in such patients. 
Three instances of delayed HIV seroconversion occurring in health-care workers have 
been reported, in these instances, the health-care workers[16] tested negative for HIV 
antibodies greater than 6 months postexposure but were seropositive within 12 months 
after the exposure. DNA sequencing confirmed the source of infection in one instance. 
Two of the delayed seroconversions were associated with simultaneous exposure to 
hepatitis C virus (HCV). In one case, co-infection was associated with a rapidly fatal HCV 
disease course; however, it is not known whether HCV directly influences the risk for or 
course of HIV infection or is a marker for other exposure-related factors. 
 
ELISA 
The enzyme-linked immunosorbent assay (ELISA), or enzyme immunoassay (EIA), was 
the first screening test commonly employed for HIV. It has a high sensitivity. 
In an ELISA test, a person's serum is diluted 400-fold and applied to a plate to which HIV 
antigens have been attached. If antibodies to HIV are present in the serum, they may bind 
to these HIV antigens. The plate is then washed to remove all other components of the 
serum. A specially prepared "secondary antibody" — an antibody that binds to human 
antibodies — is then applied to the plate, followed by another wash. This secondary 
antibody is chemically linked in advance to an enzyme. Thus the plate will contain enzyme 
in proportion to the amount of secondary antibody bound to the plate. A substrate for the 
enzyme is applied, and catalysis by the enzyme leads to a change in colour or 
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fluorescence. ELISA results are reported as a number; the most controversial aspect of 
this test is determining the "cut-off" point between a positive and negative result. 
 
Western blot 
Like the ELISA procedure, the western blot is an antibody detection test. However, unlike 
the ELISA method, the viral proteins are separated first and immobilized. In subsequent 
steps, the binding of serum antibodies to specific HIV proteins is visualized. 
Specifically, cells that may be HIV-infected are opened and the proteins within are placed 
into a slab of gel, to which an electrical current is applied. Different proteins will move with 
different speeds in this field, depending on their size, while their electrical charge is 
levelled by a surfactant called sodium lauryl sulphate. Some commercially prepared 
Western blot test kits contain the HIV proteins already on a cellulose acetate strip. Once 
the proteins are well separated, they are transferred to a membrane and the procedure 
continues similar to an ELISA: the person's diluted serum is applied to the membrane and 
antibodies in the serum may attach to some of the HIV proteins. Antibodies that do not 
attach are washed away, and enzyme-linked antibodies with the capability to attach to the 
person's antibodies determine to which HIV proteins the person has antibodies. 
There are no universal criteria for interpreting the western blot test: The number of viral 
bands that must be present may vary. If no viral bands are detected, the result is negative. 
If at least one viral band for each of the GAG, POL, and ENV gene-product groups are 
present, the result is positive. The three-gene-product approach to western blot 
interpretation has not been adopted for public health or clinical practice. Tests in which 
less than the required number of viral bands are detected are reported as indeterminate: a 
person who has an indeterminate result should be retested, as later tests may be more 
conclusive. Almost all HIV-infected persons with indeterminate western blot results will 
develop a positive result when tested in one month; persistently indeterminate results over 
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a period of six months suggests the results are not due to HIV infection. In a generally 
healthy low-risk population, indeterminate results on western blot occur on the order of 1 in 
5,000 patients. However for those individuals that have had high-risk exposures to 
individuals where HIV-2 is most prevalent, Western Africa, an inconclusive western blot 
test may prove infection with HIV-2. 
The HIV proteins used in western blotting can be produced by recombinant DNA in a 
technique called recombinant immunoblot assay (RIBA). 
 
Rapid or point-of-care tests 
Rapid antibody tests are qualitative immunoassays intended for use in point-of-care testing 
to aid in the diagnosis of HIV infection. These tests should be used in conjunction with the 
clinical status, history, and risk factors of the person being tested. The positive predictive 
value of Rapid Antibody Tests in low-risk populations has not been evaluated. These tests 
should be used in appropriate multi-test algorithms designed for statistical validation of 
rapid HIV test results. 
If no antibodies to HIV are detected, this does not mean the person has not been infected 
with HIV. It may take several months after HIV infection for the antibody response to reach 
detectable levels, during which time rapid testing for antibodies to HIV will not be indicative 
of true infection status. For most people, HIV antibodies reach a detectable level after two 
to six weeks. 
Although these tests have high specificity, false positives do occur. A lab using the 
western blot should confirm any positive test result. 
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Interpreting antibody tests 
ELISA testing alone cannot be used to diagnose HIV, even if the test suggests a high 
probability that antibody to HIV-1 is present. In the United States, such ELISA results are 
not reported as "positive" unless confirmed by a Western Blot. 
The ELISA antibody tests were developed to provide a high level of confidence that 
donated blood was NOT infected with HIV. It is therefore not possible to conclude that 
blood rejected for transfusion because of a positive ELISA antibody test is in fact infected 
with HIV. Sometimes, retesting the donor in several months will produce a negative ELISA 
antibody test. This is why a confirmatory Western Blot is always used before reporting a 
"positive" HIV test result. 
Rare false positive results due to factors unrelated to HIV exposure are found more often 
with the ELISA test than with the Western Blot. False positives may be associated with 
medical conditions such as recent acute illnesses and allergies. A rash of false positive 
tests in the fall of 1991 was initially blamed on the influenza vaccines used during that flu 
season, but further investigation traced the cross-reactivity to several relatively non-
specific test kits. A false positive result does not indicate a condition of significant risk to 
health. When the ELISA test is combined with Western Blot, the rate of false positives is 
extremely low, and diagnostic accuracy is very high (see below). 
HIV antibody tests are highly sensitive, meaning they react preferentially with HIV 
antibodies, but not all positive or inconclusive HIV ELISA tests mean HIV infects the 
person. Risk history, and clinical judgement should be included in the assessment, and a 
confirmation test (Western blot) should be administered. An individual with an inconclusive 
test should be re-tested at a later date. 
 
  
 29 
Accuracy of HIV testing 
The specificity rate given here for the inexpensive enzyme immunoassay screening tests 
indicates that, in 1,000 HIV test results of healthy individuals, about 15 of these results will 
be a false positive. Confirming the test result (i.e., by repeating the test, if this option is 
available) could reduce the ultimate likelihood of a false positive to about 1 result in 
250,000 tests given. The sensitivity rating, likewise, indicates that, in 1,000 test results of 
HIV infected people, 3 will actually be a false negative result. However, based upon the 
HIV prevalence rates at most testing centres within the United States, the negative 
predictive value of these tests is extremely high, meaning that a negative test result will be 
correct more than 9,997 times in 10,000 (99.97% of the time). The very high negative 
predictive value of these tests is why the CDC recommends that a negative test result be 
considered conclusive evidence that an individual does not have HIV. 
Of course, the actual numbers vary depending on the testing population. This is because 
interpreting of the results of any medical test (assuming no test is 100% accurate) 
depends upon the initial degree of belief, or the prior probability that an individual has, or 
does not have a disease. Generally the prior probability is estimated using the prevalence 
of a disease within a population or at a given testing location. The positive predictive value 
and negative predictive value of all tests, including HIV tests, take into account the prior 
probability of having a disease along with the accuracy of the testing method to determine 
a new degree of belief that an individual has or does not have a disease (also known as 
the posterior probability). The chance that a positive test accurately indicates an HIV 
infection increases as the prevalence or rate of HIV infection increases in the population. 
Conversely, the negative predictive value will decrease as the HIV prevalence rises. Thus 
a positive test in a high-risk population, such as people who frequently engage in 
unprotected anal intercourse with unknown partners, is more likely to correctly represent 
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HIV infection than a positive test in a very low-risk population, such as unpaid blood 
donors. 
Many studies have confirmed the accuracy of current methods of HIV testing in the United 
States, reporting false-positive rates of 0.0004 to 0.0007 and false-negative rates of 0.003 
in the general population. 
 
Management of HIV/AIDS 
Antiviral therapy 
Current HAART options are combinations (or "cocktails") consisting of at least three 
medications belonging to at least two types, or "classes," of antiretroviral agents. Initially 
treatment is typically a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two 
nucleoside analogue reverse transcriptase inhibitors (NRTIs). Typical NRTIs include: 
zidovudine (AZT) or tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC).[124] 
Combinations of agents which include a protease inhibitors (PI) are used if the above 
regimen loses effectiveness. 
When to start antiretroviral therapy is subject to debate. The World Health Organization 
recommends antiretrovirals in all adolescents, adults and pregnant women with a CD4 
count less than 500/µl with this being especially important in those with counts less than 
350/µl or those with symptoms regardless of CD4 count. This is supported by the fact that 
beginning treatment at this level reduces the risk of death. The United States in addition 
recommends them for all HIV-infected people regardless of CD4 count or symptoms; 
however it makes this recommendation with less confidence for those with higher counts. 
While the WHO also recommends treatment in those who are co-infected with tuberculosis 
and those with chronic active hepatitis B. Once treatment is begun it is recommended that 
it is continued without breaks or "holidays". Many people are diagnosed only after 
treatment ideally should have begun. The desired outcome of treatment is a long term 
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plasma HIV-RNA count below 50 copies/mL. Levels to determine if treatment is effective 
are initially recommended after four weeks and once levels fall below 50 copies/mL checks 
every three to six months are typically adequate. Inadequate control is deemed to be 
greater than 400 copies/mL. Based on these criteria treatment is effective in more than 
95% of people during the first year. 
Benefits of treatment include a decreased risk of progression to AIDS and a decreased 
risk of death. In the developing world treatment also improves physical and mental health. 
With treatment there is a 70% reduced risk of acquiring tuberculosis. Additional benefits 
include a decreased risk of transmission of the disease to sexual partners and a decrease 
in mother-to-child transmission. The effectiveness of treatment depends to a large part on 
compliance. Reasons for non-adherence include poor access to medical care, inadequate 
social supports, and mental illness and drug abuse. The complexity of treatment regimens 
(due to pill numbers and dosing frequency) and adverse effects may reduce adherence. 
Even though cost is an important issue with some medications, 47% of those who needed 
them were taking them in low and middle-income countries as of 2010 and the rate of 
adherence is similar in low-income and high-income countries. 
Specific adverse events are related to the antiretroviral agent taken. Some relatively 
common adverse events include: lipodystrophy syndrome, dyslipidemia, and diabetes 
mellitus, especially with protease inhibitors. Other common symptoms include diarrhea, 
and an increased risk of cardiovascular disease. Newer recommended treatments are 
associated with fewer adverse effects. Certain medications may be associated with birth 
defects and therefore may be unsuitable for women hoping to have children. 
Treatment recommendations for children are somewhat different from those for adults. The 
World Health Organisation recommends treating all children less than 5 years of age; 
children above 5 are treated like adults. The United States guidelines recommend treating 
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all children less than 12 months of age and all those with HIV RNA counts greater than 
100,000 copies/mL between one year and five years of age. 
 
Opportunistic infections 
Measures to prevent opportunistic infections are effective in many people with HIV/AIDS. 
In addition to improving current disease, treatment with antiretrovirals reduces the risk of 
developing additional opportunistic infections. Adults and adolescents who are living with 
HIV (even on anti-retroviral therapy) with no evidence of active tuberculosis in settings with 
high tuberculosis burden should receive isoniazid preventive therapy (IPT), the tuberculin 
skin test can be used to help decide if IPT is needed. Vaccination against hepatitis A and 
B is advised for all people at risk of HIV before they become infected; however it may also 
be given after infection. Trimethoprim/sulfamethoxazole prophylaxis between four and six 
weeks of age and ceasing breastfeeding in infants born to HIV positive mothers is 
recommended in resource limited settings. It is also recommended to prevent PCP when a 
person's CD4 count is below 200 cells/uL and in those who have or have previously had 
PCP. People with substantial immunosuppression are also advised to receive prophylactic 
therapy for toxoplasmosis and Cryptococcus meningitis. Appropriate preventive measures 
have reduced the rate of these infections by 50% between 1992 and 1997. 
 
Pulmonary  
Pneumocystis pneumonia (PCP) (originally known as Pneumocystis carinii pneumonia) is 
relatively rare in healthy, immunocompetent people, but common among HIV-infected 
individuals. It is caused by Pneumocystis jirovecii. 
Before the advent of effective diagnosis, treatment and routine prophylaxis in Western 
countries, it was a common immediate cause of death. In developing countries, it is still 
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one of the first indications of AIDS in untested individuals, although it does not generally 
occur unless the CD4 count is less than 200 cells per µL of blood. 
Tuberculosis (TB) is unique among infections associated with HIV because it is 
transmissible to immunocompetent people via the respiratory route, and is not easily 
treatable once identified. Multidrug resistance is a serious problem. Tuberculosis with HIV 
co-infection (TB/HIV) is a major world health problem according to the World Health 
Organization: in 2007, 456,000 deaths among incident TB cases were HIV-positive, a third 
of all TB deaths and nearly a quarter of the estimated 2 million HIV deaths in that year. 
Even though its incidence has declined because of the use of directly observed therapy 
and other improved practices in Western countries, this is not the case in developing 
countries where HIV is most prevalent. In early-stage HIV infection (CD4 count >300 cells 
per µL), TB typically presents as a pulmonary disease. In advanced HIV infection, TB often 
presents atypically with extrapulmonary (systemic) disease a common feature. Symptoms 
are usually constitutional and are not localized to one particular site, often affecting bone 
marrow, bone, urinary and gastrointestinal tracts, liver, regional lymph nodes, and the 
central nervous system. 
 
Gastrointestinal  
Esophagitis is an inflammation of the lining of the lower end of the oesophagus (gullet or 
swallowing tube leading to the stomach). In HIV-infected individuals, this is normally due to 
fungal (candidiasis) or viral (herpes simplex-1 or cytomegalovirus) infections. In rare 
cases, it could be due to mycobacteria. 
Unexplained chronic diarrhoea in HIV infection is due to many possible causes, including 
common bacterial (Salmonella, Shigella, Listeria or Campylobacter) and parasitic 
infections; and uncommon opportunistic infections such as cryptosporidiosis, 
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microsporidiosis, Mycobacterium avium complex (MAC) and viruses, astrovirus, 
adenovirus, rotavirus and cytomegalovirus, (the latter as a course of colitis). 
In some cases, diarrhoea may be a side effect of several drugs used to treat HIV, or it may 
simply accompany HIV infection, particularly during primary HIV infection. It may also be a 
side effect of antibiotics used to treat bacterial causes of diarrhoea (common for 
Clostridium difficile). In the later stages of HIV infection, diarrhoea is thought to be a 
reflection of changes in the way the intestinal tract absorbs nutrients, and may be an 
important component of HIV-related wasting. 
 
Neurological and psychiatric  
HIV infection may lead to a variety of neuropsychiatric sequelae, either by infection of the 
now susceptible nervous system by organisms, or as a direct consequence of the illness 
itself. 
Toxoplasmosis is a disease caused by the single-celled parasite called Toxoplasma 
gondii; it usually infects the brain, causing toxoplasma encephalitis, but it can also infect 
and cause disease in the eyes and lungs. Cryptococcal meningitis is an infection of the 
meninx (the membrane covering the brain and spinal cord) by the fungus Cryptococcus 
neoformans. It can cause fevers, headache, fatigue, nausea, and vomiting. Patients may 
also develop seizures and confusion; left untreated, it can be lethal. 
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease, in which 
the gradual destruction of the myelin sheath covering the axons of nerve cells impairs the 
transmission of nerve impulses. It is caused by a virus called JC virus which occurs in 70% 
of the population in latent form, causing disease only when the immune system has been 
severely weakened, as is the case for AIDS patients. It progresses rapidly, usually causing 
death within months of diagnosis. 
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AIDS dementia complex (ADC) is a metabolic encephalopathy induced by HIV infection 
and fuelled by immune activation of HIV infected brain macrophages and microglia. These 
cells are productively infected by HIV and secrete neurotoxins of both host and viral origin. 
Specific neurological impairments are manifested by cognitive, behavioural, and motor 
abnormalities that occur after years of HIV infection and are associated with low CD4+ T 
cell levels and high plasma viral loads. 
Prevalence is 10–20% in Western countries but only 1–2% of HIV infections in India. This 
difference is possibly due to the HIV subtype in India. AIDS related mania is sometimes 
seen in patients with advanced HIV illness; it presents with more irritability and cognitive 
impairment and less euphoria than a manic episode associated with true bipolar disorder. 
Unlike the latter condition, it may have a more chronic course. This syndrome is less 
frequently seen with the advent of multi-drug therapy. 
 
Tumors  
People with HIV infections have substantially increased incidence of several cancers. This 
is primarily due to co-infection with an oncogenic DNA virus, especially Epstein-Barr virus 
(EBV), Kaposi's sarcoma-associated herpes virus (KSHV) (also known as human 
herpesvirus-8 [HHV-8]), and human papillomavirus (HPV). 
Kaposi's sarcoma (KS) is the most common tumour in HIV-infected patients. The 
appearance of this tumour in young homosexual men in 1981 was one of the first signals 
of the AIDS epidemic. Caused by a gamma herpes virus called Kaposi's sarcoma-
associated herpes virus (KSHV), it often appears as purplish nodules on the skin, but can 
affect other organs, especially the mouth, gastrointestinal tract, and lungs. High-grade B 
cell lymphomas such as Burkitt's lymphoma, Burkitt's-like lymphoma, diffuse large B-cell 
lymphoma (DLBCL), and primary central nervous system lymphoma present more often in 
HIV-infected patients. These particular cancers often foreshadow a poor prognosis. 
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Epstein-Barr virus (EBV) or KSHV cause many of these lymphomas. In HIV-infected 
patients, lymphoma often arises in extra nodal sites such as the gastrointestinal tract. 
When they occur in an HIV-infected patient, KS and aggressive B cell lymphomas confer a 
diagnosis of AIDS. 
Invasive cervical cancer in HIV-infected women is also considered AIDS-defining; it is 
caused by human papillomavirus (HPV). 
In addition to the AIDS-defining tumours listed above, HIV-infected patients are at 
increased risk of certain other tumours, notably Hodgkin's disease, anal and rectal 
carcinomas, hepatocellular carcinomas, head and neck cancers, and lung cancer. Some of 
these are causes by viruses, such as Hodgkin's disease (EBV), anal/rectal cancers (HPV), 
head and neck cancers (HPV), and hepatocellular carcinoma (hepatitis B or C). Other 
contributing factors include exposure to carcinogens (cigarette smoke for lung cancer), or 
living for years with subtle immune defects. 
Interestingly, the incidence of many common tumours, such as breast cancer or colon 
cancer, does not increase in HIV-infected patients. In areas where HAART is extensively 
used to treat AIDS, the incidence of many AIDS-related malignancies has decreased, but 
at the same time malignant cancers overall have become the most common cause of 
death of HIV-infected patients.[30] In recent years, an increasing proportion of these 
deaths have been from non-AIDS-defining cancers. 
 
Other infections  
People with AIDS often develop opportunistic infections that present with non-specific 
symptoms, especially low-grade fevers and weight loss. These include opportunistic 
infection with Mycobacterium avium-intracellulare and cytomegalovirus (CMV). CMV can 
cause colitis, as described above, and CMV retinitis can cause blindness. 
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Penicilliosis due to Penicillium marneffei is now the third most common opportunistic 
infection (after extra pulmonary tuberculosis and cryptococcosis) in HIV-positive 
individuals within the endemic area of Southeast Asia. 
An infection that often goes unrecognized in people with AIDS is Parvovirus B19. Its main 
consequence is anaemia, which is difficult to distinguish from the effects of antiretroviral 
drugs used to treat AIDS itself. 
 
Epidemiology 
Globally, an estimated 35.3 (32.2–38.8) million people were living with HIV in 2012. An 
increase from previous years as more people are receiving the life-saving antiretroviral 
therapy. There were 2.3 (1.9–2.7) million new HIV infections globally, showing a 33% 
decline in the number of new infections from 3.4 (3.1–3.7) million in 2001. At the same 
time the number of AIDS deaths is also declining with 1.6 (1.4–1.9) million AIDS deaths in 
2012, down from 2.3 (2.1–2.6) million in 2005. As this report reveals, striking gains have 
been made towards many of the 2015 targets and elimination commitments, although 
significant challenges remain (UNAIDS 2013). 
prevalence countries have generally been favourable over the last decade, recent surveys 
in several countries in subSaharan Africa have detected decreases in condom use 
and/or an increase in the number of sexual partners. Efforts to reduce transmission related 
to sex work and men who have sex with men remain insufficient, as evidence by recent 
trends in prevalence among these groups. 
However, prospects for strengthening prevention efforts have never been more promising, 
as a series of highly effective biomedical prevention tools have emerged in recent years to 
buttress the prevention benefits of behavioural and structural approaches. Momentum 
accelerated in 2012 towards the scale-up of one such biomedical intervention – voluntary 
medical male circumcision. 
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Prevention efforts continue to bear fruit, with the number of new HIV infections among 
adults in low- and middle-income countries in 2012 being 1.9 million (1.6–2.3), which was 
30% lower than in 2001. Declining rates of new HIV infections in 26 low- and middle-
income countries are a testament to these efforts. Reductions in new infections among 
adults since 2001 primarily represent a reduction in sexual transmission, although the 
declining trend in the global number of new HIV infections among adults needs to be 
accelerated if the 2015 target is to be reached. 
While challenges persist in preventing new infections, opportunities to dramatically lower 
HIV incidence have never been more promising. In recent years, evidence has emerged 
that antiretroviral therapies can reduce the risk of HIV transmission by as much as 96%,1 
voluntary medical male circumcision by approximately 60%,2,3,4 pre-exposure 
antiretroviral prophylaxis by more than 40% among men who have sex with men5 and 
49% among people who inject drugs. 
 
 
 
 
 
 
Figure 4. Numbers of people living with 
HIV, new HIV infections, and AIDS deaths, 
2001-2012, globally (from UNAIDS 2012 
estimates, modified) 
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Figure 5. New HIV infections among adults in low- and middle-income countries, by 
region, 2001–2012 (from UNAIDS 2013 estimates, modified) 
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PART TWO 
Review of exercise interventions in people living with 
HIV infections 
Introduction 
The introduction of a combined Antiretroviral Therapy (cART) in 1996 has reduced the 
morbidity and mortality associated with Human Immunodeficiency Virus (HIV) (Palella et 
al., 1998; Collaboration ATC, 2008) becoming in this way a chronic disease. 
Globally, an estimated 35.3 (32.2–38.8) million people were living with HIV in 2012. There 
were 2.3 (1.9–2.7) million new HIV infections globally, showing a 33% decline in the 
number of new infections from 3.4 (3.1–3.7) million in 2001. At the same time the number 
of AIDS deaths is also declining with 1.6 (1.4–1.9) million AIDS deaths in 2012, down from 
2.3 (2.1–2.6) million in 2005. As of December 2012, an estimated 9.7 million people in low- 
and middle-income countries were receiving antiretroviral therapy, an increase of 1.6 
million over 2011. That brings the world nearly two-thirds of the way towards the 2015 
target of 15 million people accessing antiretroviral treatment. Under the 2010, 61% (57–
66%) of all persons eligible for HIV treatment in low- and middle-income countries had 
obtained antiretroviral therapy in 2012. Taking into account the 875.000 people receiving 
antiretroviral therapy in high-income countries, a total of 10.6 million people were receiving 
antiretroviral therapy as of December 2012 (WHO, 2013). 
Despite these impressive results, several questions still wait for an answer and several 
issues are still under debate. Furthermore, the emergences of new comorbidities that may 
be partly associated with cART therapy and partly with HIV itself represent a new problem 
in medical practice.  
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Abnormal lipid and glucose metabolism and fat redistribution with central lipohypertrophy 
and peripheral lipoatrophy, are common among cART-treated patients (Carr et al., 1998; 
Grinspoon et al., 2005). Moreover, osteoporosis and osteopenia are also increased 
(Grund et al., 2009). 
Medications may ameliorate some cART-related complications, but their use is associated 
with financial cost and potential toxicities. For these reason, safe, effective and non-
pharmacological interventions are needed to prevent and manage the side effect of 
medications and chronic inflammation seen in HIV-infected patients. 
In addition, HIV is now a chronic illness in patients with continued treatment access and 
excellent long-term adherence. Since cure is not yet possible, treated people have to 
maintain lifelong adherence and face the risk of delayed drug toxic effects (Palmisano & 
Vella, 2011). 
The aim of this review was to examine the effects of aerobic, resistance and combined 
exercise training on a variety of outcome markers, including body composition, metabolic 
profile, inflammatory markers and bone mineralisation in HIV infected people living with 
cART therapy. Based on literature findings, we suggest general models of intervention as 
practical guidance for prescribing an effective exercise protocols for this particular 
population. 
 
Methods 
Studies for this review article were identified via a systematic search on the electronic 
database of PubMed (www.pubmed.gov) including these major keywords: HIV/AIDS, 
physical activity and exercise training. In addition to computer investigation, we use 
previous review articles and references from original articles. Studies including aerobic, 
resistance and combined exercise training in people living with cART therapy published 
from January 1996 to November 2014 were selected. The following inclusion criteria were 
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chosen: (1) patients no in cART therapy; (2) other exercise intervention; (3) review articles; 
(4) studies that gave only psychological outcomes; (5) studies that described only the 
study design and baseline measurements; (6) case studies. Non-English language 
publication, unpublished studies, abstracts and conference proceeding were excluded. 
The studies are presented in chronological order. The main categories of information 
include: (1) first author and year; (2) number of subject at baseline, sex and presence of 
control group; (3) the type of exercise, length of training period, duration of session, 
frequency of session per week, intensity and volume of exercise; (4) number and 
percentage of drop-out; (5) results of the studies according to outcome measures. The 
initial search identified 72 citations. Two independent reviewers screening the titles and 
the abstracts reduced these to 21 studies after elimination of duplicates and application of 
the inclusion and exclusion criteria. These studies were finally analysed and the findings 
were divided based on outcome measures including: (1) body composition; (2) metabolic 
profile; (3) inflammation; (4) bone mineralisation. 
 
Results 
The initial search identified 72 citations (Figure 6). Two independent reviewers screening 
the titles and the abstracts reduced this to 21 studies after elimination of duplicates and 
application of the inclusion and exclusion criteria. These studies were finally analysed and 
the results were divided for: (1) body composition; (2) metabolic profile; (3) inflammation; 
(4) bone mineralisation. 
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Figure 6. Flowchart of literature search. *Reason for exclusion: patients no in cART 
therapy (n=23); other exercise intervention (n=1); review (n=21); psychological outcomes 
(n=3); study design (n=2); case study (n=1). 
   
Physical fitness outcomes 
In Table 1, are shown 21 trials that met the inclusion criteria. Fourteen studies were 
randomized controlled trial (Agin et al., 2001; Roubenoff et al., 2001; Driscoll et al., 
2004a/b; Terry et al., 2006; Dolan et al., 2006; Hand et al., 2008; Lindegaard et al., 2008; 
Gomes et al., 2010; Farinatti et al., 2010; Souza et al., 2011; Dudgeon et al., 2012; 
Broholom et al., 2013; Ezema et al., 2014), whereas seven studies have no control group 
(Roubenoff et al., 1999; Yarashesky et al., 2001; Thoni et al., 2001; Engelson et al., 2006; 
Robinson et al., 2007; Ahmad et al., 2014; Garcia et al., 2014).  
Eight trials included participants of both sexes (Roubenoff et al., 2001; Thoni et al., 2002; 
Driscoll et al., 2004a/b; Therry et al., 2006; Robinson et al., 2007; Hand et al., 2008; 
Souza et al., 2011), three studies included only women (Agin et al., 2001; Engelson et al., 
2006; Dolan et al., 2006), six trials included only men (Roubenoff et al., 1999; Yarasheski 
et al., 2001; Lindegaard et al., 2008; Dudgeon et al., 2011; Broholom et al., 2013; Ahmad 
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et al., 2014) and 3 trials not reported the sex of participants (Gomes et al., 2010; Farinatti 
et al., 2010; Ezema et al., 2014; Garcia et al., 2014).  
The total number of participants was 687, and the number of dropouts was 162 (24%).  
Ten trials used combined exercise training (Roubenoff et al., 1999; Driscoll et al., 2004a/b; 
Dolan et al., Robinson et al., 2007; Hand et al., 2008; Gomes et al., 2010; Farinatti et al., 
2010; Dudgeon et al., 2014; Garcia et al., 2014), four studies used aerobic training (Thoni 
et al., 2002; Terry et al., 2006; Ezema et al., 2014; Ahmad et al., 2014) and five studies 
used resistance training (Agin et al., 2001; Yarasheski et al., 2001; Roubenoff et al., 2001; 
Engelson et al., 2006; Souza et al., 2011). Furthermore, only one proposed the 
comparison between aerobic and resistance training (Lindegaard et al., 2008; Broholom et 
al., 2013). 
The duration of the training program ranged from 6 weeks to one year, the frequency of 
training session varied from 2 to 4 per week.  
Regarding the aerobic training activity all studies performed continuous exercise training 
with the duration from 20 to 45 minutes mainly performed indoor with stationary bike or 
treadmill. On the other hand the studies of Lindegaard et al. (2008) and Broholom et al., 
2014, subjects have to complete an interval-training program.  
The parameters to monitor the intensity of training between the various studies are 
different. The majority of the studies used the calculation of the maximal heart rate (HRmax) 
using the 220-age or the 208-(0.7*age) formula, ranging the intensity from 60 to 80% of 
HRmax (Driscoll et al., 2004a/b; Engelson et al., 2006; Terry et al., 2006; Dolan et al., 2006; 
Dudgeon et al, 2012). Four ranged the intensity of the training session it from 60 to 80% of 
max (Robinson et al., 2007; Lindegaard et al., 2008; Broholom et al., 2014; Garcia et al, 
2014) and Hand et al (2008) used instead the 50-70% of peak. In particular, the study 
of Thoni et al. (2002) used the intensity corresponding to the ventilatory threshold 
2OV&
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measured during max; the studies of Farinatti et al. (2010) and Gomes et al. (2010) 
used a workload associated with an heart rate of 150 beats per minutes (BPM) to avoid 
possible exercise-induced immunodepression; and the study of Ezema et al. (2014) used 
the 60-75% of heart rate of reserve. A different approach was used by the study of Ahmad 
et al., 2014, who train the subjects with a one-year individual marathon running plan, so 
with different distances and intensities among the training sessions. Finally, the study of 
Roubenoff et al (1999) not reported the intensity of the training sessions. 
Regarding the resistance-training program all studies used free weight, exercises 
machines and bodyweight exercises, using the 3 set of 8-12 repetition or the circuit 
training methods.  
The majority of studies used the one-repetition maximum (RM), measuring directly the 
maximal amount of weight that could be lifted one time by the target muscle group 
(Roubenoff et al., 1999; Agin et al., 2001; Yahasheski et al., 2001; Roubenoff et al., 2001; 
Driscoll et al., 2004a/b; Engelson et al., 2006; Dolan et al., 2006; Robinson et al., 2007; 
Garcia et al., 2008). The studies of Hand et al. (2008), Lindegaard et al. (2008) and 
Broholom et al. (2014) estimate the maximal load using the 3RM test, instead the study of 
Farinatti et al. (2010) and Gomes et al. (2010) estimate the maximal load using the 12RM. 
Using these methods the intensities were scheduled from 50 to 80% of RM. On the 
contrary, the study of Souza et al. (2011) used adjusted submaximal loads and the study 
of Dudgeon et al. (2012) scheduled the exercises adjusting the load so that subjects were 
able to perform 12 repetitions. 
For assessing the improvement in the physical fitness six studies assessed it directly using 
a ramp protocol until volitional exhaustion (Thoni et al., 2002; Terry et al., 2006; 
Lindegaard et al., 2008; Broholom et al., 2013; Ahamad et al., 2014; Garcia et al., 2014). 
Furthermore, three studies (Robinson et al., 2007; Hand et al., 2008; Ezema et al., 2014) 
2OV&
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used the modified Bruce protocol that estimated peak the total time spent on treadmill 
that was subsequently placed into the gender specific equations that have been validated 
for estimating peak from treadmill time during the Bruce Protocol. Moreover, the studies 
of Engelson et al. (2006) and Dudgeon et al. (2012) estimated the max from a modified 
stress test using the Balke and the Keytel protocol respectively. 
Two studies used submaximal exercise stress test to measure the grade of physical 
fitness of the patients. The study of Dolan et al. (2006) used a submaximal exercise stress 
test based on the American College of Sports Medicine equation for estimation of max 
during cycle ergometer, and in addition assesse the functional status with a 6-Minutes 
Walking Test (6MWT) at baseline and at the end of the study. The study of Farinatti et al. 
(2010), instead, used a 3-stage cycle ergometer protocol. A different approach was used 
by Souza et al. (2011), which submitted to two functional tests that included an 
assessment of a timed 2.4-meter walk at a normal pace and a timed test of five repetitions 
of rising from a chair and sitting down (sit-standing). 
Finally four studies did not report any measure of aerobic fitness (Roubenoff et al., 1999; 
Driscoll et al., 2004a/b; Gomes et al., 2010). 
2OV&
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Author Subjects Intervention Drop out Outcomes 
Roubenoff et al. 
1999 
14 men 
No control group 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on treadmill or cycle 
ergometer, intensity NR. 
− Resistance: the major muscle groups of the 
legs, back and arm (1 hour at 80% 1RM) 
4 subjects 
(28%) 
 
 
↑Leg Press (p<0.02) 
↑Leg Extension (p<0.03) 
↑Chest Press (p<0.005) 
 
Agin et al. 
2001 
37 women 
 
Prospective, randomized, 
controlled trial 
 
12 Protein supplementation 
Vs. 
12 Progressive resistance 
training 
Vs. 
13 Combined treatment 
Frequency: 3 sessions/week 
Duration: 14 weeks 
Exercise:  
− Resistance: 3 sets of 8-10 rep at 75% 1RM 
for 7 major muscle groups 
 
Protein supplementation: 1.0 g/kg/day of 
undenatured bovine derive whey protein 
powder 
 
 
7 subjects 
(19%) 
Whey protein 
↑Bench press (p=0.02) 
↑Shoulder press (p=0.02) 
↑Biceps curl (p=0.01) 
↑Triceps extension (p=0.02) 
↑Leg extension (p=0.03) 
↔ Seated back row, leg curl 
 
Exercise treatment 
↑Bench press (p<0.001) 
↑Seated back row (p<0.001) 
↑Shoulder press (p<0.001) 
↑Biceps curl (p<0.001) 
↑Triceps extension (p<0.001) 
↑Leg Extension (p<0.001) 
↑Leg curl (p<0.001) 
 
Combined treatment 
↑Bench press (p<0.001) 
↑Seated back row (p<0.001) 
↑Shoulder press (p<0.001) 
↑Biceps curl (p<0.001) 
↑Triceps extension (p<0.001) 
↑Leg Extension (p<0.001) 
↑Leg curl (p<0.001) 
Yarasheski et al. 
2001 
18 men 
No control group 
Frequency: 4 sessions/week 
Duration: 24 weeks 
Exercise: 
Resistance: 3 upper-body/4 lower-body done 
1-1.5 h/d, at 75-85% 1 RM, exercises not 
clearly stated 
None ↑RM in all six exercises (23-38%, p<0.001) 
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Roubenoff et al. 
2001 
20 men and 5 women 
6 with AIDS wasting 
vs 
19 No AIDS wasting 
Frequency: 3 sessions/week 
Duration: 8 weeks 
Exercise: 
Resistance: 3 sets of 8 reps, double leg 
press, leg extension, seated chest press, 
seated row (50% 1-RM first session, 60% 
second session, and 75%-80% for remain 
sessions)  
None No wasting 
↑Chest press, Leg press, Leg extension 
Upper back (0.01>p>0.0001) 
 
Wasting 
↑Chest press, Leg press, Leg extension 
Upper back (0.01>p>0.0001) 
Thoni et al. 
2002 
12 men and 5 women 
No control group 
Frequency: 2 session/week 
Duration: 16 weeks 
Exercise: 
Endurance: 45 min on cycle ergometer at HR 
corresponding to ventilatory threshold 
2 subjects 
(10%) 
↑VO2max (p<0.005) 
Driscoll et al. 
2004 (a, b) 
20 men and 5 women 
 
Prospective, randomized 
 
19 metformin and exercise 
vs 
18 metformin only 
Frequency: 2 sessions/week 
Duration: 12 weeks 
Exercise: combined 
− Endurance: 20 min on cycle ergometer for 
2 weeks at 60% of HRmax and 30 min at 
75% of HRmax for 10 weeks. 
− Resistance: 3 sets/10 rep, hip extension, 
lateral pull down, knee extension, elbow 
flexion, knee extension, chest press (60% 
1RM first two weeks, 70% 1RM third and 
fourth week, 80% rest of weeks) 
 
Metformin treatment: 500 mg twice a day, 
with an increase at 850 mg twice a day after 
two weeks.  
12 subjects 
(33%) 
Study one 
Metformin and exercise subjects 
↓Waist-to-hip ratio (p=0.026) 
↓Abdominal CT subcutaneous adipose tissue 
fat (p=0.049) 
↑Mid-thigh CT leg muscle area (p=0.015) 
↑CT anterior thigh muscle attenuation 
(p=0.04) 
↔Weight, BMI, DEXA total fat, abdominal CT 
visceral adipose tissue area, CT visceral 
adipose tissue area subcutaneous adipose 
tissue fat ratio 
 
Engelson et al. 
2006 
39 women 
No control group 
Frequency: 3 sessions/week 
Duration: 12 weeks 
Exercise: combined with diet 
− Endurance: 30 min on treadmill 70-80% 
HRmax 
− Resistance: 3 sets/8-10 rep, 10 exercises 
for 7 major muscle groups, 
− Diet: 5024-kJ hypo energetic 
21 subjects 
(54%) 
↑Pectoral (p<0.0001) 
↑Latissimus dorsi (p<0.0001) 
↑Quadriceps (p<0.0001) 
↑Time to fatigue (p=0.0015) 
↓RPE (p=0.03) 
Terry et al. 
2006 
26 men and 16 women 
 
Randomized controlled trial 
 
21 Endurance and diet  
Frequency: 3 sessions/week 
Duration: 12 week 
Exercise: 
− Endurance: 30 min running at 70-85% 
HRmax 
12 subjects 
(29%) 
↑VO2max (Exercise and diet) 
↔ VO2max (Diet only) 
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vs 
21 Stretching, relaxation 
program and Diet  
Daily caloric intake of 30 kcal/kg of body 
weight for women and 40 kcal/kg of body 
weight for men, with a protein intake of 2.0 
g/kg of body weight for women and 2.5 g/kg 
of body weight for men. 
Dolan et al. 
2006 
40 women 
20 exercise 
20 Non-exercise 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on cycle ergometer, 
60%HRmax 1-2 wk and 30 min, 75% 
HRmax 3-16 wk 
− Resistance: 3 sets of 10 rep 60% 1RM for 
weeks 1 and 2; 4 sets of 8 rep at 
70%1RM for week 3 and 4; 4 sets of 8 
rep at 80%1RM for weeks 5 and 16 
(knee-hip extension, bench press, knee 
flex, lat-raise, stand calf, arm curl) 
1 subject 
(5%) 
↑VO2max (p<0.001) 
↑Submaximal bike exercise time (p<0.001) 
↑Strength (p<0.001) 
↑6MWT distance (p=0.009) 
↑Knee extensors (p<0.001) 
↑Pectoralis (p<0.001) 
↑Knee flexors (p<0.001) 
↑Shoulder abductors (p<0.001) 
↑Ankle plantar flexors (p<0.001) 
↑Elbow flexors right/left (p<0.001) 
Robinson et al. 
2007 
8 men and 1 women 
No control group 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on treadmill at 70-80% 
V’O2max 
− Resistance: 2 sessions a week, 1 set of 8 
to 10 repetitions at 60-80% 1-RM (lat pull 
down, seated row, shoulder press, bench 
press, leg press, calf press, seated leg curl) 
4 subjects 
(56%) 
↔VO2max (p=0.08) 
↑Strength, sum of increase of increases in 
1RM for all seven resistance exercises 
(p=0.04) 
Hand et al. 
2008 
30 men and 10 women 
 
Randomized controlled trial 
 
30 Exercise 
40 control 
Frequency: 2 sessions/week 
Duration: 6 weeks 
Exercise: combined 
− Endurance: 30 min at 50-70% V’O2 peak 
− Resistance: 20 min at 60% 3-RM 
34 subjects 
(46%) 
↑Time to fatigue (p<0.001) 
↑Estimated VO2max (p<0.001) 
↓% Functional aerobic impairment 
↑Peak heart rate during exercise stress test 
↓HR at submaximal absolute workload 
Lindegaard et al. 
2008 
20 men 
 
Randomized controlled trial 
 
10 Endurance 
vs 
10 Strength 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: 
− Endurance: 35 min of interval training on 
treadmill (8wks at 65% of V’O2max, 8 wks of 
75% V’O2max) 
− Resistance: 3 sets of 8-12 rep at 50-80% 
3RM (leg curl, pull-down, seated leg press, 
chest press, seated rows, leg extension, 
2 subjects 
(10%) 
Endurance training 
↑VO2max (p=0.0046) 
↑3RM for six muscle groups (p=0.0044) 
 
Strength training 
↔VO2max, 3RM for six muscle groups 
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abdominal crunch, back extension) 
Gomes et al. 
2010 
29 subjects 
 
Randomized controlled trial 
 
19 Exercise group 
10 Control group 
Frequency: 3 sessions/week 
Duration: 12 weeks 
Exercise: combined 
− Endurance: 30 min at 150 bpm (treadmill/ 
cycloergometer) 
− Resistance: 3 sets/12 rep 60-80% 12RM 
(leg press, horizontal supine, leg extension, 
low rowing, abdominal flexion) 
− Flexibility: 3 sets at 30 sec/exercise (trunk, 
hip, knee, shoulder and elbow) 
None Physical fitness outcomes not reported 
Farinatti et al. 
2010 
27 subjects (gender not 
defined) 
 
Randomized controlled trial 
 
19 Exercise 
8 Control 
Frequency: 3 sessions/week 
Duration: 12 weeks 
Exercise: combined 
− Endurance: 30 min on cycle ergometer at 
150 bpm 
− Resistance: 3 sets of 12 rep at 80% of 
12RM (leg press, bench press, knee 
extension, seated bilateral row, abdominal 
sit-ups) 
Flexibility 2 sets 30 sec major joint 
None ↑Flexibility (p<0.05) 
↑Leg press (p<0.05) 
↑Seated bilateral row (p<0.05) 
↓HR at workload (p<0.05) 
 
Souza et al. 
2011 
18 men and 18 women 
 
Randomized controlled trial 
 
14 Exercise with HIV 
22 Control without HIV 
infection 
Frequency: 2 sessions/week 
Duration: 48 weeks 
Exercise: 
Resistance: 3 sets of 8-12 rep with adjusted 
sub-maximal loads (leg press, seated row, 
lumbar extension, chest press, seated 
abdominal) 
4 subjects 
(11%) 
↓Sit-Standing (p<0.001) 
↑Walking 2.4.m (p<0.001) 
↑Leg press (p<0.001) 
↑Chest press (p<0.001) 
↑Lumbar extension (p<0.001) 
↑Seated row (p<0.001) 
↑Seated abdominal (p=0.003) 
Dudgeon et al. 
2012 
111 men 
 
Randomized controlled trial 
 
52 Exercise 
59 Control with HIV 
Frequency: 2 sessions/week 
Duration: 6 weeks 
Exercise: combined 
− Endurance: 30 min on treadmill or cycle 
ergometer at 60-75% HRmax 
Resistance: circuit training for 12 rep (upper 
and lower body exercises) 
35 subjects 
(32%) 
Physical fitness outcomes not reported 
Broholom et al. 
2013 
20 men 
 
Randomized controlled trial 
 
10 Endurance 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: 
− Endurance: 35 min of interval training on 
treadmill (8wks at 65% of V’O2max, 8 wks of 
2 subjects 
(10%) 
Endurance training 
↑VO2max (p=0.0046) 
↑3RM for six muscle groups (p=0.0044) 
 
Strength training 
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vs 
10 Strength 
75% V’O2max) 
− Resistance: 3 sets of 8-12 rep at 50-80% 
3RM (leg curl, pull-down, seated leg press, 
chest press, seated rows, leg extension, 
abdominal crunch, back extension) 
↔VO2max, 3RM for six muscle groups 
 
Ezema et al. 
2014 
33 subjects with HIV 
 
Randomized controlled trial 
 
17 Exercise 
16 Control 
Frequency: 3 sessions/week 
Duration: 8 weeks 
Exercise: 
Endurance: 2 weeks for 45 min at 60-79% 
HRR; 6 weeks for 60 at 60-79% HRR 
(treadmill) 
3 subjects 
(9%) 
↑VO2max 
 
Ahmad et al. 
2014 
 
12 men 
No control group 
Individual marathon running plan 
− First week 3/wk for 3-4 hours, 60-
70%HRmax (improve aerobic metabolism) 
− 4 months, 3/wk for 6 hours, 70-80% 
HRmax (economization of metabolism and 
cardiovascular system) 
− 7 months 3/wk for 10 hours (introduction of 
3x2000m rec 800 m relaxed pace) 
− 2 weeks before marathon, tapering, 60-
70%HRmax 
4 subjects 
(33%) 
After 4-month 
↑Maximal velocity (p<0.05) 
↑Anaerobic threshold velocity (p<0.05) 
 
 
Garcia et al. 
2014 
10 subjects 
No control group 
Frequency: 3 sessions/week 
Duration: 20 weeks 
Exercise: combined 
− Resistance: circuit training, 1-4 wks 
(1circuit, 12 rep at minimal load); 5-12 wks 
(2 circuits, 15 rep at 40%1RM); 13-20 wks 
(3 circuits, 15 rep at 60% 1RM), ½ squat, 
bench press, 45° leg press, sit-ups, seated 
row, leg curl, shoulder press, triceps pulley, 
biceps curl, seated calf raise, abdominal 
crunches 
− Endurance: walking, 1-4 wks (30 min free); 
5-12 weeks (30 min at 60%V’O2max); 13-20 
(30 min at 75%V’O2max) 
None ↑Abdominal (p<0.01) 
↑VO2max (p<0.005) 
↑Squat (p<0.008) 
↑45° leg press (p<0.02) 
↑Seated row (p<0.02) 
↑Triceps extension 
↔Push-ups, bench press, leg curl, shoulder 
press, biceps curl, calf raise 
Table 1. Physical fitness outcomes. 
Legend: VO2max: Maximal Oxygen Consuption; VO2peak: Peak Oxygen Consuption; HRmax: Heart Rate Max; HRR: Heart Rate of 
Reserve; RM: Repetition Maximum. 
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Body composition outcomes 
In Table 2 shows the main findings from 18 interventional longitudinal studies that met the 
inclusion criteria. Eleven studies were randomized controlled trials (Agin et al., 2011; 
Roubenoff et al., 2001; Driscoll et al., 2004a/b; Terry et al., 2006; Dolan et al., 2006; 
Lindegaard et al., 2008; Farinatti et al., 2010; Souza et al., 2011; Dudgeon et al., 2012; 
Ezema et al., 2014), whereas seven studies had no control group (Roubenoff et al., 1999; 
Yarashesky et al., 2001; Thöni et al., 2002; Engelson et al., 2006; Robinson et al., 2007; 
Ahmad et al 2014; Garcia et al; 2014).  
Seven trials included participants of both sexes  (Roubenoff et al., 2001; Driscoll et al., 
2004a/b; Terry et al., 2006; Souza et al., 2011; Thoni et al., 2002; Robinson et al., 2007), 
three studies included only women (Agin et al., 2001; Dolan et al., 2006; Engelson et al., 
2006), five trials included only men (Lindegaard et al., 2008; Dudgeon et al., 2012; 
Roubenoff et al 1999; Yarasheski et al., 2001; Ahmad et al., 2014) and 3 trials not 
reported the sex of participants (Farinatti et al., 2010; Ezema et al., 2014; Garcia et al., 
2014). The total number of participants was 566, and the number of dropouts was 124 
(22%).  
Nine trials used combined exercise training (Roubenoff et al 1999; Driscoll et al., 2004a/b; 
Engelson et al., 2006; Dolan et al., 2006; Robinson et al., 2007; Farinatti et al., 2010; 
Dudgeon et al., 2012; Garcia et al., 2014), four studies used aerobic training (Thoni et al., 
2002; Terry et al., 2006; Ezema et al., 2004; Ahmad et al., 2014) and four studies used 
resistance training (Agin et al., 2001; Yarasheski et al., 2001; Robinson et al., 2007; Souza 
et al., 2011). Furthermore, only one proposed the comparison between aerobic and 
resistance training (Lindegaard et al., 2008). 
The protocols had a median duration of 16 weeks with a median frequency of 3 sessions 
per week. Regarding the aerobic training activity all studies performed continuous exercise 
training with the duration ranging from 20 to 45 minutes mainly performed indoor with cycle 
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ergometer (4) or treadmill (4). Moreover, the studies of Terry et al., 2006, and Garcia et al., 
2014 trained subject with running or walking without specifying how the training was 
performed. Finally, Ahamad et al., 2014 trained their subjects with a one-year individual 
running plan. 
The parameters chosen to define and monitor the intensity of aerobic training between the 
various studies varied. The majority of the studies used the calculation of HRmax using the 
220-age (Fox et al., 1971) or the 208-(0.7*age) (Tanaka et al., 2001) formula, ranging the 
training intensity from 60 to 80% of HRmax (Driscoll et al., 2004a/b; Engelson et al., 2006; 
Terry et al., 2006; Dudgeon et al, 2012). Three studies measured directly the maximal 
oxygen consumption ( max), and then setting the intensity of the training session from 
60 to 80% of max (Robinson et al., 2007; Lindegaard et al., 2008; Garcia et al, 2014). 
In particular, the study of Thoni et al. (2002) used the intensity corresponding to the 
ventilatory threshold measured during the max incremental test; the study of Farinatti 
et al. (2010) used a workload associated with an heart rate of 150 BPM to avoid possible 
exercise-induced immune-depression; and the study of Ezema et al. (2014) used the 60-
75% of heart rate of reserve (HRR, HRmax – HR at rest) (Fletcher et al., 2001). A different 
approach was used by the study of Ahmad et al., 2014, who trained the subjects with a 
one-year individual marathon running plan, so with different distances and intensities 
among training sessions. Finally, the study of Roubenoff et al (1999) did not report the 
intensity of the training sessions. 
Regarding the resistance-training program all studies used free weight, exercises 
machines and bodyweight exercises, using the 3 set of 8-12 repetition or the circuit 
training methods.  
The majority of studies used the one-RM, measuring directly the maximal amount of 
weight that could be lifted one time by the target muscle group (Roubenoff et al., 1999; 
2OV&
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Agin et al., 2001; Yahasheski et al., 2001; Roubenoff et al., 2001; Driscoll et al., 2004a/b; 
Dolan et al., 2006; Robinson et al., 2007; Garcia et al., 2008). The studies of Lindegaard 
et al. (2008) and Farinatti et al. (2010), estimate the maximal load using the 3RM test and 
the 12RM respectively. On the contrary, the study of Souza et al. (2012) used adjusted 
submaximal loads. Using these methods the intensities were scheduled from 50 to 80% of 
RM. 
For assessing the body composition parameters Dual Energy X-ray Absortiometry (DEXA), 
Computer Tomography (CT), and Magnetic Resonance Imaging (MRI) were used. In 
addition one study used also skinfold thickness for the estimation of the body density and 
percentage of body fat by the formulas of Durnin and Womersley and Siri, respectively. 
The influence of exercise training on body weight and Body Mass Index (BMI, kg · m2) 
was not supported by strong evidence; in fact only two studies reported their reduction 
(Engelson et al., 2006; Terry et al., 2006). These parameters were obviously affected by 
the exercise type in particular resistance training caused an increase of fat free mass in six 
studies (Agin et al., 2001; Yarasheski et al., 2001; Roubenoff et al., 2001; Lindegaard et 
al., 2008; Dudgeon et al., 2012; Garcia et al., 2014). 
On the other hand, nine studies reported a reduction of the parameters related to fat mass 
(Roubenoff et al 1999; Agin et al., 2001; Thoni et al., 2001; Driscoll et al., 2004a/b; 
Engelson et al., 2006; Terry et al, 2006; Robinson et al., 2007; Lindegaard et al., 2008) 
and five studies reported a reduction of morphometric parameters such as waist-to-hip 
ratio (Driscoll et al., 2004a/b; Terry et al., 2006), circumferences (Engelson et al., 2006; 
Dolan et al., 2006) and skinfolds thickness (Engelson et al., 2006). 
 
  
 55
Author Subjects Intervention Drop-out (nr) Outcomes 
Roubenoff et al. 
1999 
14 men 
No control group 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on treadmill or 
cycle ergometer, intensity NR. 
− Resistance: the major muscle groups 
of the legs, back and arm (1 hour at 
80% 1RM) 
4 subjects 
(28%) 
 
 
↓Total Body fat by DEXA (p<0.01) 
↓Trunk Fat by DEXA (p<0.03) 
↔ Weight, lean mass 
Agin et al. 
2001 
37 women 
 
Prospective, randomized, 
controlled trial 
 
12 Protein 
supplementation 
Vs. 
12 Progressive resistance 
training 
Vs. 
13 Combined treatment 
Frequency: 3 sessions/week 
Duration: 14 weeks 
Exercise:  
− Resistance: 3 sets of 8-10 rep at 75% 
1RM for 7 major muscle groups 
 
Protein supplementation: 1.0 g/kg/day of 
undenatured bovine derive whey protein 
powder 
 
 
7 subjects 
(19%) 
Protein Supplementation 
↑Body weight (p=0.001) 
↑Fat mass by MRI (p=0.002) 
↑Fat mass by DEXA (p=0.001) 
↑Fat free mass by DEXA (p=0.01) 
↔Body cell mass by TBK, skeletal muscle by MRI 
 
Exercise treatment 
↓Body cell mass by TBK (p=0.03) 
↑Skeletal muscle by MRI (p<0.001) 
↓Fat mass by MRI (p=0.02) 
↓Fat mass by DEXA (p=0.06) 
↓Fat free mass by DEXA (p=0.05) 
↔ Body weight, Body cell mass by TBK 
 
Combined treatment 
↑Body cell mass by TBK (p=0.01) 
↑Fat free mass by DEXA (p=0.05) 
↔ Body weight, skeletal muscle by MRI, fat mass 
by MRI, fat mass by DEXA 
Yarasheski et al. 
2001 
18 men 
No control group 
Frequency: 4 sessions/week 
Duration: 24 weeks 
Exercise: 
− Resistance: 3 upper-body/4 lower-
body done 1-1.5 h/d, at 75-85% 1 RM, 
exercises not clearly stated 
None ↑Body weight (<0.001) 
↑Whole body lean mass (p<0.005) 
↑Trunk lean mass (p=0.02) 
↑Arms lean mass (p=0.001) 
↑Thigh muscle area (p<0.005) 
↔Total intramuscular fat area, leg lean mass, 
whole body, trunk, arms, legs fat mass, trunk-to-
appendicular fat ratio 
Roubenoff et al. 
2001 
20 men and 5 women 
6 with AIDS wasting 
Frequency: 3 sessions/week 
Duration: 8 weeks 
None Wasting 
↑Fat free mass (p<0.05) 
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vs 
19 No AIDS wasting 
Exercise: 
− Resistance: 3 sets of 8 reps, double 
leg press, leg extension, seated chest 
press, seated row (50% 1-RM first 
session, 60% second session, and 
75%-80% for remain sessions)  
 
No wasting 
↑Fat free mass (p<0.05) 
Thoni et al. 
2002 
12 men and 5 women 
No control group 
Frequency: 2 session/week 
Duration: 16 weeks 
Exercise: 
− Endurance: 45 min on cycle ergometer 
at HR corresponding to ventilatory 
threshold 
2 subjects 
(10%) 
↓Total abdominal adipose tissue by DEXA 
(p=0.0005) 
↓Visceral adipose tissue by DEXA (p=0.004) 
↔Weight, BMI, fat free mass, fat mass, 
subcutaneous abdominal adipose tissue, 
subcutaneous abdominal adipose tissue visceral 
adipose tissue ratio:shrink 
Driscoll et al. 
2004 (a, b) 
20 men and 5 women 
 
Prospective, randomized 
 
19 metformin and 
exercise 
vs 
18 metformin only 
Frequency: 2 sessions/week 
Duration: 12 weeks 
Exercise: combined 
− Endurance: 20 min on cycle ergometer 
for 2 weeks at 60% of HRmax and 30 
min at 75% of HRmax for 10 weeks. 
− Resistance: 3 sets/10 rep, hip 
extension, lateral pull down, knee 
extension, elbow flexion, knee 
extension, chest press (60% 1RM first 
two weeks, 70% 1RM third and fourth 
week, 80% rest of weeks) 
 
Metformin treatment: 500 mg twice a 
day, with an increase at 850 mg twice a 
day after two weeks.  
12 subjects 
(33%) 
Study one 
Metformin and exercise subjects 
↓Waist-to-hip ratio (p=0.026) 
↓Abdominal CT subcutaneous adipose tissue fat 
(p=0.049) 
↑Mid-thigh CT leg muscle area (p=0.015) 
↑CT anterior thigh muscle attenuation (p=0.04) 
↔Weight, BMI, DEXA total fat, abdominal CT 
visceral adipose tissue area, CT visceral adipose 
tissue area subcutaneous adipose tissue fat ratio 
 
Engelson et al. 
2006 
39 women 
No control group 
Frequency: 3 sessions/week 
Duration: 12 weeks 
Exercise: combined with diet 
− Endurance: 30 min on treadmill 70-
80% HRmax 
− Resistance: 3 sets/8-10 rep, 10 
exercises for 7 major muscle groups, 
− Diet: 5024-kJ hypo energetic 
21 subjects 
(54%) 
↓Weight (p<0.0001) 
↓BMI (p<0.0001) 
↓Waist circumference (p=0.0003) 
↓Chest circumference (p<0.0001) 
↓Biceps skinfold (p=0.04) 
↓Abdominal skinfold (p=0.01) 
↓Thigh skinfold (p=0.04) 
↓Skeletal muscle by MRI (p=0.035) 
↓Visceral adipose tissue by MRI (p<0.0001) 
↓Subcutaneous adipose tissue by MRI 
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(p<0.0001) 
↓Total adipose tissue by MRI (p<0.001) 
↓Fat mass by DEXA (p<0.0001) 
↓Total body potassium (p=0.02) 
↓Body cell mass (p=0.02) 
↔Waist-hip ratio, mid-arm circumference, thigh 
circumference, triceps skinfold, 
visceral/subcutaneous adipose tissue ratio by 
MRI, lean mass by DEXA, total body water, 
intracellular water, 
Terry et al. 
2006 
26 men and 16 women 
 
Randomized controlled 
trial 
 
21 Endurance and diet  
vs 
21 Stretching, relaxation 
program and Diet  
Frequency: 3 sessions/week 
Duration: 12 week 
Exercise: 
− Endurance: 30 min running at 70-85% 
HRmax 
Daily caloric intake of 30 kcal/kg of body 
weight for women and 40 kcal/kg of 
body weight for men, with a protein 
intake of 2.0 g/kg of body weight for 
women and 2.5 g/kg of body weight for 
men. 
12 subjects 
(29%) 
In both groups: 
↓Weight (p=0.005) 
↓BMI (p<0.003) 
↓Waist-to-hip ratio (p<0.0001) 
↓Body density (p<0.0001) 
↓Body Fat (p<0.0001) 
 
Dolan et al. 
2006 
40 women 
20 exercise 
20 Non-exercise 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on cycle 
ergometer, 60%HRmax 1-2 wk and 30 
min, 75% HRmax 3-16 wk 
− Resistance: 3 sets of 10 rep 60% 
1RM for weeks 1 and 2; 4 sets of 8 
rep at 70%1RM for week 3 and 4; 4 
sets of 8 rep at 80%1RM for weeks 5 
and 16 (knee-hip extension, bench 
press, knee flex, lat-raise, stand calf, 
arm curl) 
1 subject 
(5%) 
↓Waist circumference (p=0.03) 
↓Total muscle area (p=0.02) 
↓Total muscle attenuation (p=0.03) 
↔BMI, total fat, subcutaneous adipose tissue, 
visceral adipose tissue 
Robinson et al. 
2007 
8 men and 1 women 
No control group 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on treadmill at 70-
80% V’O2max 
− Resistance: 2 sessions a week, 1 set 
4 subjects 
(56%) 
↓Total fat by DEXA (p<0.05) 
↓Trunk fat by DEXA 
↔Visceral fat area, subcutaneous fat area, total 
lean tissue by DEXA, trunk lean tissue by DEXA, 
limb fat by DEXA. 
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of 8 to 10 repetitions at 60-80% 1-RM 
(lat pull down, seated row, shoulder 
press, bench press, leg press, calf 
press, seated leg curl) 
Lindegaard et al. 
2008 
20 men 
 
Randomized controlled 
trial 
 
10 Endurance 
vs 
10 Strength 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: 
− Endurance: 35 min of interval training 
on treadmill (8wks at 65% of V’O2max, 
8 wks of 75% V’O2max) 
− Resistance: 3 sets of 8-12 rep at 50-
80% 3RM (leg curl, pull-down, seated 
leg press, chest press, seated rows, 
leg extension, abdominal crunch, back 
extension) 
2 subjects 
(10%) 
Endurance training 
↔Body weight, total lean mass, total fat mass, 
trunk fat mass, limb fat mass 
 
Strength training 
↓Body weight (p<0.05) 
↑Total lean mass (p<0.05) 
↓Total fat mass (p<0.05) 
↓Trunk fat mass (p<0.05) 
↓Limb fat mass (p<0.05) 
Farinatti et al. 
2010 
27 subjects (gender not 
defined) 
 
Randomized controlled 
trial 
 
19 Exercise 
8 Control 
Frequency: 3 sessions/week 
Duration: 12 weeks 
Exercise: combined 
− Endurance: 30 min on cycle ergometer 
at 150 bpm 
− Resistance: 3 sets of 12 rep at 80% of 
12RM (leg press, bench press, knee 
extension, seated bilateral row, 
abdominal sit-ups) 
− Flexibility 2 sets 30 sec major joint 
None ↔Body mass, BMI 
Souza et al. 
2011 
18 men and 18 women 
 
Randomized controlled 
trial 
 
14 Exercise with HIV 
22 Control without HIV 
infection 
Frequency: 2 sessions/week 
Duration: 48 weeks 
Exercise: 
− Resistance: 3 sets of 8-12 rep with 
adjusted sub-maximal loads (leg 
press, seated row, lumbar extension, 
chest press, seated abdominal) 
4 subjects 
(11%) 
↔Body mass, BMI 
Dudgeon et al. 
2012 
111 men 
 
Randomized controlled 
trial 
 
52 Exercise 
59 Control with HIV 
Frequency: 2 sessions/week 
Duration: 6 weeks 
Exercise: combined 
− Endurance: 30 min on treadmill or 
cycle ergometer at 60-75% HRmax 
− Resistance: circuit training for 12 rep 
(upper and lower body exercises) 
35 subjects 
(32%) 
↑Total lean tissue mass (p<0.001) 
↔Body mass, BMI, fat mass, % total body fat, % 
trunk fat, % arm fat, %leg fat, arm/leg/trunk lean 
tissue mass 
Ezema et al. 33 subjects with HIV Frequency: 3 sessions/week 3 subjects ↔BMI 
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2014  
Randomized controlled 
trial 
 
17 Exercise 
16 Control 
Duration: 8 weeks 
Exercise: 
− Endurance: 2 weeks for 45 min at 60-
79% HRR; 6 weeks for 60 at 60-79% 
HRR (treadmill) 
(9%) 
Ahmad et al. 
2014 
 
12 men 
No control group 
Individual marathon running plan 
− First week 3/wk for 3-4 hours, 60-
70%HRmax (improve aerobic 
metabolism) 
− 4 months, 3/wk for 6 hours, 70-80% 
HRmax (economization of metabolism 
and cardiovascular system) 
− 7 months 3/wk for 10 hours 
(introduction of 3x2000m rec 800 m 
relaxed pace) 
− 2 weeks before marathon, tapering, 
60-70%HRmax 
4 subjects 
(33%) 
After for months of training 
↔BMI 
Garcia et al. 
2014 
10 subjects 
No control group 
Frequency: 3 sessions/week 
Duration: 20 weeks 
Exercise: combined 
− Resistance: circuit training, 1-4 wks 
(1circuit, 12 rep at minimal load); 5-12 
wks (2 circuits, 15 rep at 40%1RM); 
13-20 wks (3 circuits, 15 rep at 60% 
1RM), ½ squat, bench press, 45° leg 
press, sit-ups, seated row, leg curl, 
shoulder press, triceps pulley, biceps 
curl, seated calf raise, abdominal 
crunches 
− Endurance: walking, 1-4 wks (30 min 
free); 5-12 weeks (30 min at 
60%V’O2max); 13-20 (30 min at 
75%V’O2max) 
None ↑Percentage of lean mass (p=0.007) 
↑Total lean mass (p=0.05) 
↔Total mass, percentage of fat mass, total fat 
mass, BMI 
Table 2. Body composition outcomes 
Legend: VO2max: Maximal Oxygen Consuption; VO2peak: Peak Oxygen Consuption HRmax: Heart Rate Max; HRR: Heart Rate of 
Reserve; RM: Repetition Maximum; wks: weeks; TBK: Total Body Potassium Counting; MRI: Magnetic Resonance Imaging; DEXA: 
Dual Energy X-Ray Absortiometry; BMI: Body Mass Index; CT: Computer Tomography 
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Metabolic profile outcomes 
In Table 3, shows the results of the 13 interventional longitudinal studies that met the 
inclusion criteria. Eight studies were randomized controlled trial (Driscoll et al., 2004a/b; 
Terry et al., 2006; Dolan et al., 2006; Lindegaard et al., 2008; Souza et al., 2011; 
Broholom et al., 2013; Ezema et al., 2014), whereas five studies had no control group 
(Yarasheski et al., 2001; Thoni et al., 2002; Robinson et al., 2007; Ahmad et al., 2014; 
Garcia et al., 2014).  
Six trials included participants of both sexes (Thoni 2002; Driscoll et al., 2004a/b; Terry et 
al., 2006; Robinson et al., 2007; Souza et al., 2011), one studies included only women 
(Dolan et al., 2006), four trials included only men (Yarasheski et al., 2001; Lindegaard et 
al., 2008; Broholom et al., 2014; Ahmad et al., 2014) and two trials did not reported the 
sex of participants (Ezema et al., 2014; Garcia et al., 2014). The total number of 
participants was 333, and the number of dropouts was 59 (17%). 
 Five trials used combined exercise training (Driscoll et al., 2004a/b; Dolan et al., 2006; 
Robinson et al., 2007; Garcia et al., 2014), four studies used aerobic training (Thoni et al., 
2002; Terry et al., 2006; Ezema et al., 2014; Ahmad et al., 2014) and two studies used 
resistance training (Yarasheski et al., 2001; Souza et al., 2011). Furthermore, two studies 
proposed the comparison between aerobic and resistance training (Lindegaard et al., 
2008; Broholom et al., 2013). 
The protocols had a median duration of 16 weeks with a median frequency of 3 sessions 
per week.  
Regarding the aerobic training activity all studies performed continuous exercise training 
with the duration ranging from 20 to 45 minutes mainly performed indoor with cycle 
ergometer (three) or treadmill (four). In addition, the studies of Roubenoff et al, 1999 and 
Dudgeon et al., 2012 used both training methods. Moreover, the studies of Terry et al., 
2006, and Garcia et al., 2014 trained subject with running or walking without specifying 
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how the training was performed. Finally, Ahamad et al., 2014 trained their subjects with a 
one-year individual running plan. 
The parameters chosen to define and monitor the intensity of training between the various 
studies were different. Five studies used the calculation of the HRmax using the 220-age 
(Fox et al., 1971) or the 208-(0.7*age) formula, and then setting the intensity from 60 to 
80% of HRmax (Driscoll et al., 2004a/b; Terry et al., 2006; Dolan et al., 2006; Ahmad et al., 
2014). Four studies measured directly the max, ranging the intensity of the training 
session from 60 to 80% of max (Robinson et al., 2007; Lindegaard et al., 2008; 
Broholom et al., 2014; Garcia et al., 2014). In particular, the study of Thoni et al. (2002) 
used the intensity corresponding to the ventilatory threshold measured during the VO2max 
incremental test, and the study of Ezema et al. (2014) used the 60-75% of HRR (Fletcher 
et al., 2001). A different approach was used by the study of Ahmad et al., 2014, who 
trained the subjects with a one-year individual marathon running plan, so with different 
distances and intensities among training sessions. 
Regarding the resistance-training program all studies used free weight, exercises 
machines and bodyweight exercises, using the 3 set of 8-12 repetition or the circuit 
training methods.  
The majority of studies used the 1-RM, measuring directly the maximal amount of weight 
that could be lifted one time by the target muscle group (Yarasheski et al., 2001; Driscoll et 
al., 2004a/b; Robinson et al., 2007; Garcia et al., 2014). The studies of Lindegaard et al. 
(2008), Brohlom et al. (2013) and Farinatti et al. (2010), estimate the maximal load using 
the 3RM test and the 12RM respectively. On the contrary, the study of Souza et al. (2012) 
used adjusted submaximal loads. Using these methods the intensities were scheduled 
from 50 to 80% of RM. 
2OV&
2OV&
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The metabolic parameters were assessed by standard laboratory analysis. The influence 
of exercise training on blood lipids was not supported with strong evidence, only four 
studies reported a reduction of triglycerides (Yarasheski et al., 2001; Thoni et al., 2002; 
Lindegaard et al., 2008; Ahmad et al., 2014). Surprisingly, the study of Lindegaard et al 
(2008) reported a reduction of this parameter in the subjects that performed the resistance 
training and not the endurance protocol. In addition the study of Ahmad et al., (2014), 
which trained the subjects for one year with a individual marathon training program 
observed a reduction of triglycerides after 4 months of training but not on the marathon 
day after a tapering period. Moreover, only two studies reported a reduction of total 
cholesterol (Thoni et al., 2008; Lindegaard 2008). In particular the study of Lindegaard et 
al. (2008), observed this reduction in the group, which performed the endurance training. 
Furthermore, only the study of Lindegaard et al. (2008) observed a reduction of LDL-
cholesterol for both groups of training, instead three studies reported an improvement of 
HDL-cholesterol (Thoni et al., 2002; Lindegaard et al., 2008; Garcia et al., 2014). 
The same can be said for the insulin parameters. In fact only the study of Driscoll et al., 
(2004b) reported a reduction of fasting insulin, but the exercise program was supported by 
a Metformin treatment for 500 mg twice a day, with an increase at 850 mg twice a day 
after two weeks. A different approach was used by the study of Broholom et al., (2013) 
where HIV-infected patients with lipodystrophy have decreased insulin-stimulated glucose 
uptake in skeletal muscle and defects in insulin-stimulated phosphorylation of Aktthr308. 
Endurance and strength training increase insulin-stimulated glucose uptake in these 
patients, and the muscular training adaptation was associated with improved capacity for 
phosphorylation of glucose by HKII, rather than changes in markers of insulin signalling to 
glucose uptake or glycogen synthesis. 
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Author Subjects Intervention Drop out Outcomes 
Yarasheski et al. 
2001 
18 men 
No control group 
Frequency: 4 sessions/week 
Duration: 24 weeks 
Exercise: 
Resistance: 3 upper-body/4 lower-body done 
1-1.5 h/d, at 75-85% 1 RM, exercises not 
clearly stated 
None ↓Serum Triglycerides (p=0.022) 
↔Total cholesterol, HDL-c, LDL-c, Insulin, C-
peptide, proinsulin, glucagon 
Thoni et al. 
2002 
12 men and 5 women 
No control group 
Frequency: 2 session/week 
Duration: 16 weeks 
Exercise: 
Endurance: 45 min on cycle ergometer at HR 
corresponding to ventilatory threshold 
2 subjects 
(10%) 
↓Total cholesterol (p=0.005) 
↑HDL-c (p=0.01) 
↓Triglycerides (p<0.003) 
↓Total cholesterol HDL-c ratio (p=0.0007) 
↓Triglycerides HDL-c ratio (p=0.003) 
↔LDL-c, glucose, insulin, IR-HOMA 
Driscoll et al. 
2004 (a, b) 
20 men and 5 women 
 
Prospective, randomized 
 
19 metformin and exercise 
vs 
18 metformin only 
Frequency: 2 sessions/week 
Duration: 12 weeks 
Exercise: combined 
− Endurance: 20 min on cycle ergometer for 
2 weeks at 60% of HRmax and 30 min at 
75% of HRmax for 10 weeks. 
− Resistance: 3 sets/10 rep, hip extension, 
lateral pull down, knee extension, elbow 
flexion, knee extension, chest press (60% 
1RM first two weeks, 70% 1RM third and 
fourth week, 80% rest of weeks) 
 
Metformin treatment: 500 mg twice a day, 
with an increase at 850 mg twice a day after 
two weeks.  
12 subjects 
(33%) 
Study one 
Metformin and exercise subjects 
↓Waist-to-hip ratio (p=0.026) 
↓Abdominal CT subcutaneous adipose tissue 
fat (p=0.049) 
↑Mid-thigh CT leg muscle area (p=0.015) 
↑CT anterior thigh muscle attenuation 
(p=0.04) 
↔Weight, BMI, DEXA total fat, abdominal CT 
visceral adipose tissue area, CT visceral 
adipose tissue area subcutaneous adipose 
tissue fat ratio 
 
Terry et al. 
2006 
26 men and 16 women 
 
Randomized controlled trial 
 
21 Endurance and diet  
vs 
21 Stretching, relaxation 
program and Diet  
Frequency: 3 sessions/week 
Duration: 12 week 
Exercise: 
− Endurance: 30 min running at 70-85% 
HRmax 
− Daily caloric intake of 30 kcal/kg of body 
weight for women and 40 kcal/kg of body 
weight for men, with a protein intake of 2.0 
g/kg of body weight for women and 2.5 
g/kg of body weight for men. 
12 subjects 
(29%) 
In both groups: 
↓Glucose (p=0.05) 
 
↔ Systolic and diastolic blood pressure, 
triglycerides, total-C, HDL-C 
Dolan et al. 
2006 
40 women 
20 exercise 
Frequency: 3 sessions/week 
Duration: 16 weeks 
1 subject 
(5%) 
↔Systolic and diastolic blood pressure, total-
C, triglycerides, LDL-C, HDL-C, fasting 
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20 Non-exercise Exercise: combined 
− Endurance: 20 min on cycle ergometer, 
60%HRmax 1-2 wk and 30 min, 75% 
HRmax 3-16 wk 
− Resistance: 3 sets of 10 rep 60% 1RM for 
weeks 1 and 2; 4 sets of 8 rep at 
70%1RM for week 3 and 4; 4 sets of 8 
rep at 80%1RM for weeks 5 and 16 
(knee-hip extension, bench press, knee 
flex, lat-raise, stand calf, arm curl) 
glucose, 2-h glucose 
Robinson et al. 
2007 
8 men and 1 women 
No control group 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on treadmill at 70-80% 
V’O2max 
− Resistance: 2 sessions a week, 1 set of 8 
to 10 repetitions at 60-80% 1-RM (lat pull 
down, seated row, shoulder press, bench 
press, leg press, calf press, seated leg curl) 
4 subjects 
(56%) 
↔Total-C, LDL-C, HDL-C, triglycerides, beta-
cell function, insulin sensitivity. 
Lindegaard et al. 
2008 
20 men 
 
Randomized controlled trial 
 
10 Endurance 
vs 
10 Strength 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: 
− Endurance: 35 min of interval training on 
treadmill (8wks at 65% of V’O2max, 8 wks of 
75% V’O2max) 
− Resistance: 3 sets of 8-12 rep at 50-80% 
3RM (leg curl, pull-down, seated leg press, 
chest press, seated rows, leg extension, 
abdominal crunch, back extension) 
2 subjects 
(10%) 
Endurance training 
↓Total-C (p=0.0023) 
↑HDL-C (p<0.0001) 
↓LDL-C (p=0.0001) 
↓Fat free acid (p=0.017) 
↔Glucose, insulin, triglycerides 
 
Strength training 
↑HLD-C (p=0.0068) 
↓LDL-C (p=0.04) 
↓Triglycerides (p<0.001) 
↓Fat free acid (0.008) 
↔Glucose, insulin, total cholesterol 
Souza et al. 
2011 
18 men and 18 women 
 
Randomized controlled trial 
 
14 Exercise with HIV 
22 Control without HIV 
infection 
Frequency: 2 sessions/week 
Duration: 48 weeks 
Exercise: 
Resistance: 3 sets of 8-12 rep with adjusted 
sub-maximal loads (leg press, seated row, 
lumbar extension, chest press, seated 
abdominal) 
4 subjects 
(11%) 
↓Fat glycaemia (p=0.037) 
↔Total-C, HDL-C, LDL-C, triglycerides,  
Broholom et al. 20 men Frequency: 3 sessions/week 2 subjects Effect of insulin on HIV patients 
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2013  
Randomized controlled trial 
 
10 Endurance 
vs 
10 Strength 
Duration: 16 weeks 
Exercise: 
− Endurance: 35 min of interval training on 
treadmill (8wks at 65% of V’O2max, 8 wks of 
75% V’O2max) 
− Resistance: 3 sets of 8-12 rep at 50-80% 
3RM (leg curl, pull-down, seated leg press, 
chest press, seated rows, leg extension, 
abdominal crunch, back extension) 
(10%) ↑Phosphorylation of Aktthr308 (p<0.0001) 
↑Ratio of AS160thr624/AS160 (p<0.001) 
↑Ratio GSK3Bser9/GSK3B (p<0.05) 
↑Phosphorylation GS (p<0.0001) 
↑GS activity as % of I-form (p<0.0001) 
↑GS activity as fractional velocity (p<0.0001) 
↔GS total activity 
 
Endurance 
↑Phosphorylation of Aktthr308 (p<0.0001) 
↓pGS (site 3a+b)/ GS (p<0.01) 
↔Ratio of AS160thr624/AS160, Ratio 
GSK3Bser9/GSK3B 
 
Strength 
↑Phosphorylation of Aktthr308 (p<0.0001) 
↓Ratio of AS160thr624/AS160 (p<0.001) 
↑Ratio GSK3Bser9/GSK3B 
↑pGS (site 3a+b)/ GS (p<0.0001) 
Ezema et al. 
2014 
33 subjects with HIV 
 
Randomized controlled trial 
 
17 Exercise 
16 Control 
Frequency: 3 sessions/week 
Duration: 8 weeks 
Exercise: 
Endurance: 2 weeks for 45 min at 60-79% 
HRR; 6 weeks for 60 at 60-79% HRR 
(treadmill) 
3 subjects 
(9%) 
↓Diastolic blood pressure 
↔Systolic blood pressure 
Ahmad et al. 
2014 
 
12 men 
No control group 
Individual marathon running plan 
− First week 3/wk for 3-4 hours, 60-
70%HRmax (improve aerobic metabolism) 
− 4 months, 3/wk for 6 hours, 70-80% 
HRmax (economization of metabolism and 
cardiovascular system) 
− 7 months 3/wk for 10 hours (introduction of 
3x2000m rec 800 m relaxed pace) 
− 2 weeks before marathon, tapering, 60-
70%HRmax 
4 subjects 
(33%) 
After four months of training 
↓Triglycerides (p<0.05) 
↔LDL-C, HDL-C 
 
Marathon day 
↔LDL-C, HDL-C, triglycerides, glucose 
 
Garcia et al. 
2014 
10 subjects 
No control group 
Frequency: 3 sessions/week 
Duration: 20 weeks 
Exercise: combined 
− Resistance: circuit training, 1-4 wks 
None ↑HDL-C (p=0.04) 
↔Glucose, insulin, HOMA-IR, total-C, 
triglycerides, VLDL-C, LDL-C 
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(1circuit, 12 rep at minimal load); 5-12 wks 
(2 circuits, 15 rep at 40%1RM); 13-20 wks 
(3 circuits, 15 rep at 60% 1RM), ½ squat, 
bench press, 45° leg press, sit-ups, seated 
row, leg curl, shoulder press, triceps pulley, 
biceps curl, seated calf raise, abdominal 
crunches 
− Endurance: walking, 1-4 wks (30 min free); 
5-12 weeks (30 min at 60%V’O2max); 13-20 
(30 min at 75%V’O2max) 
Table 3. Metabolic profile outcomes 
Legend: VO2max, Maximal Oxygen Consuption; VO2peak, Peak Oxygen Consuption; HRmax, Heart Rate Max; HRR, Heart Rate of 
Reserve; RM, Repetition Maximum; wks, weeks; TBK, Total Body Potassium Counting; MRI, Magnetic Resonance Imaging; AUC, 
Area Under the Curve; GS, Glucose Sintetase, HDL-C, high-density lipoprotein, LDL-C, low-density lipoprotein; VLDL-C, very low-
density lipoprotein; Aktthr308, Phosphorylation of Aktthr308; AS160thr624/AS160, Phosphorylation of AS160thr642 related to total AS160 
protein expression; GSK3Bser9/GSK3B, Phosphorylation of GSK3bser9 related to total GSK3b protein expression; GS: Activity 
measures of glycogen synthase. 
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Inflammation outcomes 
In Table 4, shows the results of the only 2 interventional longitudinal studies that met the 
inclusion criteria (Lindegaard et al., 2008; Dudgeon et al., 2012). Both studies included 
male patients that were subsequently randomized. The total number of participants was 
131, and the number of dropouts was 37 (28%).  
The study of Lindegaard et al. (2008) proposed an exercise intervention for 16 week at 3 
sessions a week, but made a comparison between endurance and resistance training 
program. The endurance program was performed indoor on treadmill, and consisted of 35 
minutes of interval training at 65-75% of max. The endurance program was performed 
with machines at an intensity of 50-80% of 3RM. 
On the contrary, the study of Dudgeon et al. (2012) proposed an exercise intervention for 
6 weeks of combined exercise training 2 sessions a week. The aerobic training program 
was performed indoor on treadmill or stationary bike for 30 minutes at 60-75% of HRmax 
measured by 220-age formula (Fox et al., 1971). In addition, the resistance training was 
made with the circuit training method with adjusted intensity that allowed subjects to 
perform 12 repetitions. 
Lindegaard et al. (2008) reported that the endurance-training program reduced the values 
of high-sensitivity C-reactive protein (hsCRP), Tumor Necrosis Factor-alpha (TNF-alpha), 
Interleukin-6 (IL-6) and Interleukin-18 (IL-18). In addition the subject that performed the 
strength-training program reported a reduction only in IL-18, and not in the other 
parameters evaluated. 
On the contrary, the study of Dudgeon et al. (2012), reported only a reduction in salivary 
cortisol, whereas no variation were detected in all the other parameters such as IL-6, 
interleukin-1- β (IL-1-β), soluble tumour necrosis factor receptor II  (sTNFrII), insulin-like 
growth factor-1 (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), growth 
hormone (GH), cortisol, testosterone . 
2OV&
 68 
Generally, cART-controlled chronic HIV infection is associated with increased inflammation 
and coagulation, and higher plasma levels of hsCRP, IL-6 and D-dimer strongly predicted 
higher overall mortality and cardiovascular events. However, the anti-inflammatory effect 
of exercise in HIV infection has been rarely addressed in clinical studies. Reductions of 
hsCRP, IL-6, TNF- and IL-18, a cytokine released by adipocytes and other cell types, 
were observed in a 16-week study of aerobic or resistance training performed at variable 
intensity (Lindegaard et al., 2008), but no of IL-6 after 6 weeks of aerobic plus resistance 
moderate intensity exercise (Dudgeon et al., 2012). Looking these encouraging results we 
suggest that are needed more studies that assess the anti-inflammatory effect of exercise 
in HIV infection. 
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Author Subjects Intervention Drop out Outcomes 
Lindegaard et al. 
2008 
20 men 
 
Randomized controlled trial 
 
10 Endurance 
vs 
10 Strength 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: 
− Endurance: 35 min of interval training on 
treadmill (8wks at 65% of V’O2max, 8 wks of 
75% V’O2max) 
− Resistance: 3 sets of 8-12 rep at 50-80% 
3RM (leg curl, pull-down, seated leg press, 
chest press, seated rows, leg extension, 
abdominal crunch, back extension) 
2 subjects 
(10%) 
Endurance training 
↓hsCRP (p<0.0001) 
↓TNF-alpha (p=0.009) 
↓IL-6 (p=0.01) 
↓IL-18 (p=0.029) 
 
Strength training 
↓IL-18 (p<0.0001) 
↔hsCRP, TNF-alpha, IL-6,  
Dudgeon et al. 
2012 
111 men 
 
Randomized controlled trial 
 
52 Exercise 
59 Control with HIV 
Frequency: 2 sessions/week 
Duration: 6 weeks 
Exercise: combined 
− Endurance: 30 min on treadmill or cycle 
ergometer at 60-75% HRmax 
− Resistance: circuit training for 12 rep 
(upper and lower body exercises) 
35 subjects 
(32%) 
↓Salivary cortisol after exercise (p<0.05) 
↔IL-6, IL-1, sTNFrII, IGF-1, IGFBP-3, growth 
hormone, cortisol, salivary testosterone 
 
Table 4. Inflammatory outcomes 
Legend: VO2max, Maximal Oxygen Consuption; VO2peak, Peak Oxygen Consuption HRmax, Heart Rate Max; HRR, Heart Rate of 
Reserve; RM, Repetition Maximum; wks, weeks; hsCRP, high-sensitivity C-Reactive Protein; TNF-alpha, Tumor Necrosis Factor-
alpha; IL-6, Interleukin-6; IL-18, Interleukin-18; IGF-1, Insulin-like Growth Factor 1; IGFBP-3, Insulin-like growth factor-binding protein 
3
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Bone mineralisation outcomes 
In Table 5, shows findings from the 2 interventional longitudinal studies that met the 
inclusion criteria (Roubenoff et al., 1999; Engelson et al., 2006). Both studies had no 
control group. The study of Roubenoff et al. (1999) enrolled only male subjects, whereas 
the study of Engelson et al. (2006) only female patients. The total number of participants 
was 53, and the number of dropouts was 25 (47%). 
 Both trials used the combined exercise training with the duration of 16 (Roubenoff et al., 
1999) and 12 weeks (Engelson et al., 2006), at 3 sessions a week. Regarding the aerobic 
training activity all studies performed continuous exercise training with the duration of 20 
(Roubenoff et al., 1999) and 30 minutes (Engelson et al., 2006) mainly performed indoors 
with stationary bike or treadmill. The study of Roubenoff et al. (1999) did not report the 
intensity of exercise; instead Engelson et al. (2006) scheduled the exercise at 70-80% of 
HRmax calculated by the 220-age formula (Fox et al., 1971). 
Regarding the resistance-training program all studies used free weight, exercises 
machines and bodyweight exercises, using the 3 set of 8-12 repetition or the circuit 
training methods. Both studies used the 1-RM method for assess the intensity of the 
resistance exercises.  
The parameters of bone mineralisation were assessed by DEXA. Neither study reported 
variations in bone mineral density and bone calcium. BMC, Z- e T-score not assessed 
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Author Subjects Intervention Drop out Outcomes 
Roubenoff et al. 
1999 
14 men 
No control group 
Frequency: 3 sessions/week 
Duration: 16 weeks 
Exercise: combined 
− Endurance: 20 min on treadmill or cycle 
ergometer, intensity NR. 
− Resistance: the major muscle groups of the 
legs, back and arm (1 hour at 80% 1RM) 
4 subjects 
(28%) 
 
 
↔Bone mineral density by DEXA 
Engelson et al. 
2006 
39 women 
No control group 
Frequency: 3 sessions/week 
Duration: 12 weeks 
Exercise: combined with diet 
− Endurance: 30 min on treadmill 70-80% 
HRmax 
− Resistance: 3 sets/8-10 rep, 10 exercises 
for 7 major muscle groups, 
− Diet: 5024-kJ hypo energetic 
21 subjects 
(54%) 
↔Bone calcium, bone mineral density by 
DEXA 
Table 5. Bone mineralisation outcomes  
Legend: VO2max, Maximal Oxygen Consuption; VO2peak, Peak Oxygen Consuption HRmax, Heart Rate Max; HRR, Heart Rate of 
Reserve; RM, Repetition Maximum; wks, weeks; DEXA, Dual Energy X-Ray Absortiometry.
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Discussion 
The wide spread introduction of cART for HIV infection had dramatically decrease HIV-
morbidity and mortality  (Palella et al., 1998; Collaboration ATC, 2008) becoming in this 
way a chronic disease. Despite marked increases in life expectancy, mortality rates among 
HIV-infected persons remain 3-15 times higher than those seen in the general population 
(Guaraldi et al., 2011). Although, some of excess mortality observed among HIV-infected 
persons can be directly attributed to illnesses that occur as a consequence of 
immunodeficiency, more than half of the deaths observed in recent years among cART-
experienced HIV-infected patients are attributable to non-infectious comorbidities (Guaraldi 
et al., 2011). These include cardiovascular diseases, hypertension, bone fractures, renal 
failure, and diabetes mellitus, diseases that in the general populations often coexist and 
are associated with advancing age (Guaraldi et al., 2011). 
Regular physical activity and exercise are associated with numerous physical health 
benefits in the general population. In fact, all-cause mortality is delayed by regularly 
engaging in physical activity; this is also the case when an individual increases physical 
activity by changing from a sedentary lifestyle or a lifestyle with insufficient levels of 
physical activity to one that achieves recommended physical activity levels. Exercise and 
physical activity decrease the risk of developing cardio-vascular diseases (CVD), stroke, 
type-2 diabetes and some form of cancer (e.g. colon and breast cancers). Exercise and 
physical activity lower blood pressure; improve lipoprotein profile; C-reactive protein and 
other CVD biomarkers; enhance insulin sensitivity, and play an important role in weight 
management. Of particular relevance to older adults, exercise preserves bone mass and 
reduces the risk of falling. 
Several studies were conducted to assess the benefits an exercise intervention in people 
living with HIV infections treated with cART. The most investigated parameters concerned 
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the body composition and metabolic profile outcomes. Moreover, the inflammatory and 
bone mineralisation outcomes were also assessed. 
 
Physical fitness outcomes 
None of the examined papers investigated directly the decrease the risk of developing 
cardio-vascular diseases following a program of physical activity. On the other hand, nine 
studies assessed the level of physical fitness measuring directly of estimating the 
max, that is an important indicator of the functionality of the cardiorespiratory system. In 
particular eight studies reported an improvement of max (Thoni et al., 2002; Terry et 
al., 2006; Dolan et al., 2006; Hnd et al., 2008; Lindegaard et al., 2008; Brohlom et al., 
2013; Ezema 2014; Garcia et al., 2014) and one did not detected any variation in max 
(Robinson et al., 2007). Relationship, between cardiorespiratory fitness, biological risk 
factors and clinical health outcomes tend to parallel those for physical activity: apparently 
health middle-aged and older adults with greater cardiorespiratory fitness at baseline, and 
those who improve fitness over time have a lower risk of all-cause and CVD mortality and 
morbidity. A decreased risk of clinical events is also associated with greater 
cardiorespiratory fitness in individual pre-existing disease. Generally, cardiorespiratory 
exercises reduces several cardio-metabolic disease risk factors, although the magnitude of 
effects is modest, varies according to individual and exercise program characteristics, and 
a change in one cardio-metabolic risk factors apparently occurs independently of a change 
in another (Garber et al., 2011). Favourable improvements in hypertension, glucose 
intolerance, insulin resistance, dyslipidaemia and inflammatory markers have been 
reported in middle aged and older persons exercising within the volumes and quality of 
exercise recommended here, even during weight regain (Garber et al., 2011). The benefits 
of exercise on cardio metabolic risk factors are acute (lasting hours to days) and chronic, 
2OV&
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highlighting the value of regular exercise participation on most days of the week (Garber et 
al., 2011). 
 
Body composition outcomes 
Eighteen studies analysed how exercise training affected the parameters of body 
composition in this population. 
Several aspects were analysed in order to assess the efficacy of exercise intervention on 
body composition outcomes. In addition to the general morphometric parameters such as 
weight, BMI, circumferences and skinfold thickness, was also determined the differences 
in fat mass and fat free mass using DEXA. 
Principally, was observed a reduction of the fat mass and an improvement of fat free mass 
following a period of physical activity. On the other hand this, was not observed for weight 
and BMI because these parameters were obviously affected by the exercise type in 
particular resistance training caused an increase of fat free mass. 
In the general population physical exercise is generally play an important role in the weight 
management looking for a reduction of body composition parameters. In the domain of 
body composition outcomes overall and abdominal obesity are associated with increased 
risk of adverse health outcomes whereas greater fat free mass is associated with a lower 
risk of all-cause mortality (Garber et al., 2011). 
 
Metabolic profile outcomes 
Thirteen studies analysed how exercise training affected the parameters of metabolic 
profile out comes in this population.  
From a clinical standpoint, a remarkable observation was the general reduction of total 
cholesterol, the reduction of LDL cholesterol. Total, HDL and LDL cholesterol are each 
independent strong predictors of CVD in the general population and elevated LDL is the 
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primary target for cholesterol-lowering therapy. While high intensity aerobic exercise is 
followed by favourable cholesterol alterations, the influence of moderate intensity aerobic 
and of resistance training is not clearly evidence-supported. Only a few studies have 
examined the effects of exercise on blood lipids in HIV infection, with inconsistent 
outcomes, likely resulting from large variability of populations and exercise interventions.  
 
Inflammatory outcomes 
Only two studies how exercise training affected the parameters of inflammatory outcomes 
in HIV-infected patients, with one study that reported a general reduction on the 
parameters of chronic inflammation.  
Broad systemic immune activation is characteristic of untreated HIV infection. A robust 
activation and inflammatory state are seen during acute infection, which is often reflected 
clinically ad “viral syndrome”. These clinical manifestations typically resolve ad markers of 
inflammation attenuate but still remain relatively and persistently elevated. Inflammatory 
and coagulation indices are typically and persistently elevated during untreated therapies. 
Whit application of cART therapy these markers improve but persistent immune activation, 
inflammation and coagulation abnormalities persist. 
In the general population a prolonged inflammatory state has detrimental health effects 
and predispose of both disability and mortality even in the absence of clinical diseases. On 
the other hand lifestyle behavioural interventions, including changes in food dietary/intake 
and physical activity, may have clinically significant benefits for improving inflammation 
over the long term (Beavers et al., 2010). Observational data from large population cohort 
studies consistently show an association between physical activity and inflammation. 
Moreover, data from intervention studies designed to examine the effects of exercise 
training on inflammation reflect less consistent findings than the data from observational 
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studies. Finally, cross sectional evidence showing that a higher volume of physical activity 
is associated with a lower systemic inflammation. 
 
Bone mineralisation outcomes 
Only two studies how exercise training affected the parameters bone mineralisation in HIV-
infected patients, but they did not report variation in the bone mineralisation outcomes. 
Osteoporosis is common in human immunodeficiency virus (HIV)–infected populations and 
is likely to become an important cause of morbidity and mortality as the HIV-infected 
population ages (Walker & Brown 2012). Data are emerging that suggest the increased 
risk of osteoporosis translates into a higher risk of osteoporosis-related fracture. In a 
population-based study at a large US healthcare system, the period prevalence of 
fractures of the spine, hip, and wrist, sites commonly associated with osteoporosis was 
60% higher in HIV-infected men and women compared with HIV-uninfected persons 
(Walker & Brown 2012). Similar results have been found in the Veterans Aging Cohort 
Study and HIV Outpatient Study. Early detection of osteoporosis, prior to the clinical 
presentation of fracture, and institution of appropriate treatment can decrease the burden 
of osteoporosis-associated fractures in HIV-infected persons. HIV-infected patients are 
also at increased risk for osteonecrosis of the hip and other bones. 
The causes of bone complications have not been fully elucidated but could be related to 
establish osteoporosis risk factors (i.e. smoking, opiate use, alcohol use), to the HIV 
infection per se or to the effect of antiretroviral drugs (in particular, protease inhibitors—PIs 
and tenofovir—TDF) (Torti et al., 2011). 
Like in the general population, and in particular in post-menopausal women, physical 
activity could play an important role for improve bone mineralisation also in HIV-infected 
patients. 
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Conclusions 
According to our literature search, this is the first review that divided the effect of exercise 
intervention looking at different outcomes in people living with HIV infection treated with 
cART. Although our conclusions are useful, there are several limitations when interpreting 
these findings. For example we include trials with and without control groups, whereas 
other methodological differences on exercise protocol, the large variability of populations 
and different exercise interventions may confound the conclusions. Furthermore, the 
heterogeneity of the level of physical fitness, state of HIV infection, possible other 
medications may considerably influence the final results.  
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PART THREE 
A pilot study of brisk walking in sedentary 
cART-treated patients 
 
Aim of Study 
Physical activity delays all-cause mortality in the general population and reduces the risk 
of cardiovascular disease (CVD), stroke, type-2 diabetes and some types of cancer 
(Garber et al., 2011). These diseases are associated with chronic inflammation, which is 
characterized by activation of inflammatory signalling pathways with abnormal production 
of cytokines and other mediators (Hotamisligil, 2006). Observational studies of large 
population cohorts consistently showed an association between physical inactivity and 
low-grade systemic inflammation and interventional studies a reduction of inflammatory 
markers following exercise (Beavers et al., 2010). 
Chronic inflammation is also a predominant feature of treated HIV infection (Lederman et 
al., 2013; Deeks et al., 2013). 
Compared to age-matched HIV-negative subjects, persons with chronic HIV infection are 
at higher risk to develop non-AIDS related chronic diseases (Guaraldi et al., 2013), and 
several studies have shown an association between chronic inflammation and higher 
cardiovascular risk and overall mortality (Kuller et al., 2008; Duprez et al., 2012). 
We hypothesized that, like in the general population, physical exercise could decrease 
inflammation in HIV infection. We designed a pilot study of moderate physical activity, 
consisting of brisk walking, with or without strength exercise, with the objective to assess 
its effects on metabolic parameters and inflammatory markers in treated HIV-infected 
persons. 
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Material and methods 
Study design 
This was a 12-week pilot study, which enrolled sedentary HIV-infected patients receiving 
combination antiretroviral treatment (cART). Inclusion criteria were: age ≥18 years; cART 
for ≥6 months; sedentary lifestyle, defined as physical activity for <2 days per week for <20 
minutes per session; either evidence of lipodystrophy or of at least one of the Adult 
Treatment Panel III definition criteria of the metabolic syndrome (NCEP, 2002). 
Exclusion criteria included any disease requiring hospitalization in the 6 weeks before 
enrolment; medical conditions contraindicating exercise as established by a sport medicine 
specialist; inability to walk at brisk pace; current substance or alcohol abuse. San Raffaele 
Hospital Ethical Committee approved the study. Written informed consent was obtained 
from all study participants. 
 
Participant screening and protocol 
Subjects were screened for eligibility by an infectious diseases specialist (SB, PC) and a 
sport medicine specialist (GM), after performing electrocardiogram at rest and during sub-
maximal cycle ergometer test. Patients who met the above inclusion criteria and with no 
contraindications to exercise were offered to either join the ‘walk’ group, consisting of brisk 
walking only, or the ‘strength-walk’ group, where each walking session was preceded by a 
strength exercise session. 
Groups of 10-15 subjects trained three times a week for 12 weeks in the periods March-
July, 2011 and 2012. The walking sessions were performed outdoor for 60 min at an 
intensity of 65-75% of maximal HR (HRmax), (Tanaka et al., 2001). Each subject was 
equipped with a personal HR monitor (Polar FT4, Polar Electro 2011, Kempele, Finland) 
with an acoustic warning if HR was below or exceeded the predetermined range. Mean HR 
(HRmean) was recorded during each session, with values captured every 5 seconds. 
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Strength exercise was carried out before walking in a gym by circuit training, including 
crunch, lat machine, chest press, leg press, leg extension, sitting calf. Each exercise was 
repeated 12 times for three sets at 65% of 1-Repetition Maximum Test (1-RM). 
Professional coaches (MB, GP, ALT) followed all the sessions providing technical 
instruction, supervision and encouragement. Participants received generic dietary advice. 
Study variables were assessed at baseline (BL) and at the end (W12) of the program. 
 
 
Figure 8. Flowchart of the study. 
 
Physical Fitness Evaluation 
6 Minutes Walking Test (6MWT). Participants were instructed to walk as fast as possible 
for six minutes on a 400 m outdoor athletic track (ATS, 2002). HRmean was recorded 
during the test, blood lactate concentration was assessed before and 3 minutes after 
6MWT (Lactate ProTM, Arkray KdK, Japan), and the Rating of Perceived Exertion (RPE) 
(Borg, 1998) before and at the end of 6MWT. 
 
Strength measurements. 1-RM test assessed the maximal load lifted in one repetition, and 
the 30-seconds crunch test the number of crunches performed in 30 seconds. 
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Body composition 
Anthropometric variables included weight, body mass index (BMI), waist, hip, and thigh 
circumference on dominant side. Total and % fat mass at arms, limbs, trunk and as total 
body was measured by dual-energy X-ray absorptiometry (DEXA)(Lunar Prodigy, version 
8.8, GE Medical Systems, Madison, WI). Superficial and visceral fat was measured by 
ultrasonography at the periumbilical skin-point (Schwenk, 2002). 
 
Laboratory analysis 
Blood examination included complete blood count; standard biochemical exams with 
fasting total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, 
triglycerides, glucose, insulin, HbA1c; CD4+ and CD8+ T-cell counts, HIV-1-RNA plasma 
level (Abbott RealTime HIV-1 assay). The Homeostatic Model Assessment (HOMA)-I and 
the Veterans Aging Cohort Study Risk (VACS) indexes were calculated (Justice et al., 
2013). 
 
Inflammatory markers 
Soluble markers. Soluble biomarkers were measured in cryopreserved plasma samples, 
drawn at BL and W12, by commercially available enzyme-linked immunosorbent assays 
according to manufacturers’ recommendation. These included high-sensitivity C-reactive 
protein (hsCRP), interleukin-6 (IL-6) and soluble CD14 (sCD14)(R&D Systems, 
Minneapolis, MN), D-dimer (Asserachrom, Diagnostica Stago, Asnieres-Sur-Seine, 
France), interleukin-18 (IL-18)(Medical and Biological Laboratories, Nagoya, Japan) and 
myostatin (Cusabio Biotech, Wuhan, China). 
 
Flow cytometry for cell-activation markers. T-cell activation was measured on 
cryopreserved peripheral blood mononuclear cells isolated by Ficoll-Paque gradient from 
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EDTA-anticoagulated whole blood. After thawing and PBS-washing, 3 x 105 cells were 
stained using phycoerythrin (PE)-conjugated anti-HLA-DR, PE-cyanin red 5.1-conjugated 
anti-CD38, Alexa Fluor 647-conjugated anti-CD3, fluorescein isothiocyanate-conjugated 
anti-CD4 or anti-CD8 (BD-Biosciences, San Diego, CA). CD38+ and HLA-DR+ cells were 
gated from the CD3+/CD4+ or CD3+/CD8+ cells on a 2-dimensional dot plot. Analyses 
were performed by FACSCalibur with CellQuest software (BD-Biosciences) and results 
reported as percentages of CD3+/CD4+ and CD3+/CD8+ T-cells expressing both HLA-DR 
and CD38. 
 
Statistical Analysis 
Quantitative variables were expressed as median and 25-75% interquartile (Q1-Q3). 
Changes between BL and W12 were assessed by Wilcoxon matched-pairs signed rank 
test, BL values and % change differences between groups by Mann-Whitney test, and 
correlations of continuous variables by the Spearman’s test. Statistical analysis was 
performed using Graph Pad Prism Software, version 6.0 for Macintosh (Graph Pad 
Software, San Diego, CA). Level of significance was set at 0.05. 
 
Results 
Patient disposition and baseline characteristics 
Fifty-nine subjects underwent a screening visit and 49 were enrolled: 29 in the walk group 
and 20 the strength-walk group. Fourteen subjects dropped out and were not included in 
the analyses (Figure 9). Fourteen subjects stopped the activity after a median of 5 weeks 
(range, 2-7) because unable to handle family or work commitments (walk group, n=5; 
strength-walk group, n=5); medical problems unrelated to the study (walk group, n=2; 
strength-walk group, n=1); “exercise too hard” (walk group, n=1). Thirty-five subjects were 
evaluated at W12, including 21 in the walk group and 14 in the strength-walk group. 
 83 
 
Figure 9. Of 59-screened patients, 49 were enrolled and 35 completed the study. 
Fourteen subjects stopped the activity after a median of 5 weeks (range, 2-7) because 
unable to handle family or work commitments (walk group, n=5; strength-walk group, 
n=5); medical problems unrelated to the study (walk group, n=2; strength-walk group, 
n=1), “exercise too hard” (walk group, n=1) 
 
 
BL patients’ characteristics are shown in Table 6. Except from gender, there was no 
difference between the two training subgroups in demographic and clinical variables. 
Because all women trained in the walking group, post-exercise changes were also 
separately analysed according to gender. 
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All 
(n=36) 
Walk 
(n=21) 
Strength-Walk 
(n=14) 
Demographics 
   
Male gendera 26, 74% 12, 57% 14, 100% 
Age (years, median, Q1-Q3) 48 (44-54) 48 (43 (54) 49 (44-54) 
Caucasian race  35 (100%) 21 (100%) 14 (100%) 
    
Risk Group 
   
Ex-intravenous drug users 8 (23%) 7 (33%) 1 (7%) 
Men-having-sex-with-men 21 (57%) 7 (33%) 13 (93%) 
Heterosexual infection 6 (17%) 6 (29%) 0 
Vertical infection 1 (3%) 1 (5%) 0 
    
HIV infection variables 
   
AIDS-defining events  9 (25%) 7 (33%) 2 (14%) 
Nadir CD4+ T-cells/µL (median, Q1-Q3) 94 (37-197) 80 (34-140) 188 (77-258) 
CD4+ T-cells/µL (median, Q1-Q3) 577 (406-726) 485 (374-686) 624 (527-740) 
VL<40 c/mL 34 (97%) 21 (100%) 13 (93%) 
Hepatitis C virus coinfection 4 (11%) 4 (19%) 0 
VACS Index 12 (5-19) 16 (6-24) 9 (0-12) 
    
Smoking and Treatments 
   
Smokers 8 (23%) 6 (29%) 2 (14%) 
NRTI+Protease inhibitor 14 (40%) 7 (33%) 7 (50%) 
NRTI+NNRTI 11 (31%) 7 (33%) 4 (29%) 
Other ART regimens 10 (28%) 7 (33%) 3 (21%) 
Beta blockersb 6 (17%) 5 (24%) 1 (7%) 
Other anti-hypertensive drugsb 5 (14%) 2 (10%) 3 (21%) 
Statinsb 10 (29%) 4 (19%) 6 (42%) 
Fibratesb 2 (6%) 0 2 (14%) 
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Inclusion criteria 
   
Lipodystrophy  35 (100%) 21 (100%) 14 (100%) 
≥1 metabolic syndrome criterion  32 (91%) 3 (14%) 0 
Blood triglycerides 150 ≥ mg/dL 14 (40%) 8 (38%) 6 (42%) 
Blood HDL-C ≤ 40 (m) or ≥50 (w) mg/d 12 (34%) 9 (43%) 3 (21%) 
Blood glucose 50 ≥ 100 mg/dL 1 (3%) 0 1 (7%) 
Waist ≥ 102 (m) or ≥ 88 cm (women) 10 (28%) 8 (38%) 2 (14%) 
SBP ≥ 150 or DBP ≥85 mmHg 12 (34) 7 (33%) 5 (36%) 
Table 6. Participants characteristics at baseline. Values are expressed as number of 
patients (%) where no otherwise indicated. 
a. Walk vs. strength-walk, p=0.005. 
b. Chronic treatment, with no changes during the training period or the 6 weeks before 
training. 
Legend: VACS, Veterans Ageing Cohort Study; NRTI, nucleoside reverse transcriptase 
inhibitors; NNRTI, non nucleoside reverse transcriptase inhibitors; m, men; w, women; 
SBP, systolic blood pressure; DBP, diastolic blood pressure. 
 
Physical Fitness 
Performance during the training sessions. Median overall adherence to the sessions was 
67%. Participants walked a median distance of 122 km in 12 weeks (5040 m each 
session) at a median exertion of 66% HRmax (Table 7). Participants in the strength-walk 
group walked longer distances than those in the walk group, both in each session and as a 
total. No different performances were observed between women and men within the walk 
group (Table 8). 
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 All 
(n=35) 
Walk 
(n=21) 
Strength-walk 
(n=14) 
Adherence (%) 67 
(58-75) 
61 
(56-72) 
69 
(63-79) 
HRmean (%HRmax)a 66 
(62-75) 
66 
(58-73) 
70 
(63-86) 
Walked distance/session (m) 5040 
(4380-5500) 
4740b 
(3535-5390) 
5330b 
(4980-5700) 
Total walked distance (km) 122 
(84-146) 
105c 
(73-139) 
136c 
(121-155) 
Table 7. Participants performance during the 12 weeks of training. Values as expressed 
as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-
pairs signed rank test. (a) The median HRmean value was calculated for each participant 
through all her/his walking sessions, to derive the median HRmean value of all participants 
(b) Walk vs. strength-walk group, p=0.027 (Mann-Whitney test). (c) Walk vs. strength-walk 
group, p=0.029 (Mann-Whitney test). HR, heart rate. 
 
 
 
 
       
  Walk 
(n=21) 
  Women  
(n=9) 
 Men  
(n=12) 
 
 
 
      
Adherence (%)  61 (56-72)   
58 
(54-65)  
66 
(61-82) 
Total walked distance (Km)  105 
b
 
(73-139)   
76 
(67-123)  
107 
(88-181) 
Walked distance/session (m)  4740 
c
 
(3535-5390)   
4000 
(3445-5330)  
4755 
(4388-5400) 
HRmean (% of HRmax) a  66 (58-73)   
66 
(63-77)  
63 
(56-68) 
 
       
Table 8. Participants performance during the 12 weeks of training. Values as expressed as 
median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs 
signed rank test. 
a. The median HRmean value was calculated for each participant through all her/his 
walking sessions, to derive the median HRmean value of all participants 
b. Walk vs. strength-walk group, p=0.027 (Mann-Whitney test) 
c. Walk vs. strength-walk group, p=0.029 (Mann-Whitney test)  
Legend: HR, heart rate.  
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6MWT. At W12 6MWT, participants walked for a significantly longer distance compared to 
BL both in the overall sample and in the two subgroups (Figure 10), in parallel with 
significant increases of HRmean, HRmax and delta lactate (Table 9). The distance 
improvement from BL did not differ between subgroups and between women and men. 
Overall, better distance improvement correlated with higher adherence (r=0.580; 
p=0.0003) and longer walked distance (r=0.555; p=0.0005) during the 12 weeks of 
training. 
 
 
Figure 10. Comparison of participants’ performance during the 6MWT. Values as 
expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon 
matched-pairs signed rank test (****p<0.0001). 
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Women (n=9) 
  
Men (n=12) 
 BL W12 p   BL W12 p  
 
   
 
   
Distance (m) 620 (577-712) 
697 
(614-775) 
0.00
2 
 
625 
(591-705) 
717 
(695-816) 0.004 
HRmean (bpm) 127 (119-148) 
138 
(118-164) n.s 
 
113 
(99-119) 
122 
(110-144) 0.002 
HRmean (%HRmax) 73 
a
 
(68-85) 
80 
(67-91) n.s 
 
62 a 
(59-79) 
69 
(67-81) 0.002 
∆[La-](mmol/L) 0.5 (0.2-3.7) 
1.2 
(0.5-3.7) n.s 
 
0.8 
(0.1-1.7) 
3.4 
(1.9-6.1) 0.003 
∆ RPE  0.5 (0.0-1.8) 
0.0 
(0.0-0.5) n.s 
 
0.8 
(0.1-2.0) 
1.8 
(0.6-2.5) n.s 
 
   
 
   
Table 9. Physical fitness values by the 6 Minutes Walking Test (6MWT) at baseline (BL) 
and week-12 (W12) in the walk group divided by gender. Values as expressed as median 
(Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed 
rank test. 
a. At BL, women had higher %HRmean than men (p=0.021, Mann-Whitney test) 
Legend: HR, heart rate; ∆[La-], difference in lactate blood concentration between before 
and after 6MWT; ∆ RPE, difference in Rate of Perceived Exertion between before and 
after 6MWT.  
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1-RM and 30-seconds crunch tests. In the strength-walk group, training was followed by 
improvement of all strength exercises (Figure 11). 
 
Figure 11. Comparison of participants’ performance during the 1RM of the exercises of 
the circuit training. Values as expressed as median (Q1-Q3). W12 values were compared 
to BL values by the Wilcoxon matched-pairs signed rank test (*p<0.05; ***p<0.001). 
 
Body composition 
Significant reductions were observed of weight, BMI and waist and hip circumference in 
the whole group. Weight, BMI reduction, hip and waist circumference reductions were 
maintained in the walk group, but none in the strength-walk group (Figure 12). Within the 
walk group, neither BMI nor waist circumference was significantly reduced when women 
and men were analysed separately (Table 11). 
No significant changes were observed of total or % fat by DEXA, or of superficial, visceral 
or total fat by ultrasonography (Table 10 and Table 11). 
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Figure 12. Comparison of participants’ variations in Body Mass Index, waist and hip 
circumference. Values as expressed as median (Q1-Q3). W12 values were compared to 
BL values by the Wilcoxon matched-pairs signed rank test (*p<0.05; **p<0.01). 
 1 
Laboratory examinations 2 
At W12, significant reductions were observed of total and LDL cholesterol in the whole 3 
sample. Both were decreased also in the walk group, and LDL cholesterol in the strength-4 
walk group (Figure 13 and Table 10). Changes from BL did not differ between groups. No 5 
cholesterol improvement was observed in women (Table 11). 6 
Among 25 statin-untreated patients, total, LDL, and also HDL cholesterol improved 7 
significantly both in the overall sample and in the walk group, and both total and LDL 8 
cholesterol were decreased in the strength-walk group (Table 12). No significant changes 9 
were observed of the other laboratory examinations (Table 10 and Table 11). 10 
 11 
 
Figure 13. Comparison of participants’ variations in Total Cholesterol, LDL-Cholesterol, 
HDL-Cholesterol. Values as expressed as median (Q1-Q3). W12 values were compared to 
BL values by the Wilcoxon matched-pairs signed rank test (*p<0.005; **p<0.01). 
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Inflammatory markers 1 
Soluble and cell inflammatory markers were examined in a total of 25 and 16 patients, 2 
respectively. Overall, we observed significant decreases of all soluble markers, except for 3 
sCD14, and of the proportion of CD8+/CD38+/HLA-DR+, but not of CD4+/CD38+/HLADR+ 4 
cells (Figure 14). HsCRP and the proportion of CD8+/CD38+/HLA-DR+ decreased 5 
significantly in both walk and strength-walk groups; IL-6 and D-dimer in the walk group 6 
only and myostatin in the strength-walk group only. Changes from BL did not differ 7 
between training groups. Significant IL-6 and D-dimer reductions were also observed in 8 
women (Table 11). We neither observed significant intercorrelations between changes of 9 
inflammatory markers, nor between inflammatory markers and other variables changes, 10 
except for a more marked decrease of myostatin in participants who walked longer total 11 
distances during training (r=-0.340, p=0.032, Spearman’s correlation). 12 
 
Figure 14. Soluble and cell inflammatory markers at baseline (BL) and week-12 (W12). 
Twenty-five patients were evaluated for soluble markers (walk, n=15; strength-walk, n=10), 
and 16 for cell markers (walk, n=10; strength-walk, n=6). 
For each group, first and second columns represent values at BL and W12, respectively. 
Horizontal bars indicate median and Q1-Q3 values. HsCRP, high sensitivity C-reactive 
protein; IL-6, interleukin-6; IL-8, interleukin-18; sCD14, soluble CD14. 
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All (n=35) Walk (n=21) Strength-Walk (n=14) 
 
BL W12 p value BL W12 p value BL W12 p value 
Physical fitness 
         
6 Minute Walking Test 
         
Distance (m) 642 
(605-715) 
730 
(695-830) 
<0.0001 620 
(590-701) 
700 
(660-807) 
<0.0001 684 
(634-724) 
792 
(714-850) 
<0.0001 
HRmean (bpm) 119 
(107-132) 
137 
(116-152) 
<0.0001 118 
(107-135) 
128 
(116-154) 
0.0003 121 
(107-133) 
138 
(116-153) 
0.004 
HRmean (%HRmax) 69 
(63-75) 
73 
(63-75) 
<0.0001 69 
(59-75) 
71 
(63-83) 
<0.0001 69 
(63-75) 
75 
(68-79) 
0.0005 
∆[La-](mmol/L) 0.9 
(0.2-2.2) 
1.9 
(0.5-4.1) 
n.s 0.8 
(0.0-2.3) 
1.2 
(0.5-2.6) 
n.s 1.0 
(0.6-2.1) 
3.3 
(0.7-4.5) 
n.s 
∆ Rate of Perceived Exertion 
(RPE) 
1.0 
(0-1) 
0.5 
(0-2) 
n.s 0.5 
(0.0-2.0) 
0.5 
(0.0-0.2) 
n.s 1.0 
(0.0-1.0) 
0.5 
(0.2-2.0) 
n.s 
1-Repetition Maximum n.a. n.a.  n.a. n.a.     
Crunch (number) n.a. n.a.  n.a. n.a.  20 
(17-22.0) 
30 
(23-34) 
0.0002 
Lat machine (kg) n.a. n.a.  n.a. n.a.  50 
(44-55) 
58 
(55-61) 
0.0002 
Chest press (kg) n.a. n.a.  n.a. n.a.  55 
(48-61) 
78 
(60-80) 
0.0007 
Leg extension (kg) n.a. n.a.  n.a. n.a.  40 50 0.014 
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(39-45) (45-51) 
Leg press (kg) n.a. n.a.  n.a. n.a.  207 
(146-242) 
240 
(187-300) 
0.002 
Sitting calf (kg) n.a. n.a.  n.a. n.a.  53 
(43-55) 
70 
(59-75) 
0.0004 
          
Body Composition 
         
Anthropometrics 
         
Weight (kg) 75 
(65-80) 
72 
(64-78) 
0.0003 75 
(63-80) 
71 
(60-77) 
0.0001 76 
(71-81) 
74 
(71-79) 
n.s 
BMI (kg/m2) 25.8 
(22.2-27.5) 
25.6 
(22.2-27.2) 
0.004 25.3 
(21.6-27.5) 
24.9 
(21.2-27.0) 
0.0098 25.8 
(24.1-26.9) 
25.0 
(23.9-27.0) 
n.s 
Waist Circumference (cm) 93 
(86-102) 
92 
(84-100) 
0.05 93 
(82-103) 
94 
(83-100) 
0.046 94 
(88-100) 
92 
(88-99) 
n.s 
Hip Circumference (cm) 95.0 
(91.0-99.5) 
94.0 
(90.0-99.5) 
0.04 97.3 
(93.8-
101.5) 
95.0 
(90.0-
101.0) 
n.s 92.0 
(91.0-99.0) 
92.0 
(89.0-97.0) 
n.s 
Leg Circumference (cm) 53.0 
(49.4-56.8) 
53.0 
(49.0-55.7) 
n.s 53.0 
(47.5-56.0) 
52.0 
(48.0-55.0) 
n.s 53.5 
(50.6-57.8) 
53.0 
(50.0-57.5) 
n.s 
DEXA 
         
Arm Fat (kg) 1.7 1.7 n.s 1.7 1.7 n.s 1.4 1.6 n.s 
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(1.2-2.5) (0.9-2.6) (1.3-3.0) (0.9-2.7) (0.7-1.9) (0.9-2.6) 
Arm Fat (%) 22.4 
(15.4-29.3) 
23.3 
(11.2-31.4) 
n.s 24.3 
(16.8-35.6) 
26.5 
(11.7-35.5) 
n.s 21.2 
(13.8-26.7) 
21.3 
(11.2-25.9) 
n.s 
Leg Fat (kg) 3.3 
(2.2-5.6) 
3.4 
(2.4-6.4) 
n.s 3.3 
(2.2-6.1) 
3.1 
(1.8-7.9) 
n.s 3.4 
(2.5-5.3) 
3.5 
(3.1-6.1) 
n.s 
Leg Fat (%) 17.5 
(11.1-26.4) 
17.1 
(11.5-25.9) 
n.s 18.5 
(12.3-28.1) 
19.1 
(9.1-20.4) 
n.s 16.8 
(9.5-27.2) 
15.6 
(11.5-24.3) 
n.s 
Trunk Fat (kg) 11.9 
(8.4-15.4) 
11.6 
(7.1-15.9) 
n.s 13.4 
(6.4-16.2) 
14.2 
(5.4-16.0) 
n.s 10.9 
(9.1-12.4) 
11.4 
(7.7-12.1) 
n.s 
Trunk Fat (%) 30.8 
(24.2-38.9) 
31.8 
(22.2-38.9) 
n.s 30.9 
(21.9-39.9) 
34.6 
(20.9-40.1) 
n.s 30.4 
(25.5-36.3) 
30.2 
(23.1-35.3) 
n.s 
Tot Fat (kg) 17.7 
(12.1-22.3) 
17.7 
(10.0-23.5) 
n.s 19.6 
(11.0-28.1) 
20.8 
(9.4-26.5) 
n.s 16.9 
(12.7-18.5) 
17.5 
(11.2-18.6) 
n.s 
Tot Fat (%) 25.1 
(19.7-
36.40) 
25.8 
(15.5-32.7) 
n.s 25.7 
(191.1-
38.3) 
26.9 
(15.3-38.0) 
n.s 24.7 
(22.1-32.9) 
24.3 
(16.9-30.9) 
n.s 
Trunk-to-Limb Fat Ratio 1.7 
(1.2-2.1) 
1.7 
(1.1-2.5) 
n.s 1.6 
(1.1-1.8) 
1.6 
(1.1-1.9) 
n.s 1.8 
(1.1-2.8) 
1.8 
(1.2-2.8) 
n.s 
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Ultrasonography          
Superficial Fat (mm) 17.0 
(11.8-28.2) 
16.0 
(12.0-30.3) 
n.s 18.0 
(12.4-29) 
18.7 
(13.0-32.5) 
n.s 12.0 
(8.0-23.5) 
13.0 
(9.0-18.0) 
n.s 
Visceral Fat (mm) 60.0 
(52.5-75.5) 
64.0 
(49.8-77.8) 
n.s 59.0 
(46.5-70.0) 
61.0 
(38.5-69.5) 
n.s 68.0 
(57.0-83.0) 
69.0 
(61.0-90.0) 
n.s 
Total Fat (mm) 82.0 
(70.3-97.5) 
80.0 
(72.5-99.5) 
n.s 83.5 
(70.3-
102.8) 
81.0 
(59.0-
101.5) 
n.s 81.5 
(68.0-93.5) 
80.0 
(77.0-99.0) 
n.s 
          
Laboratory examinations 
         
Haemoglobin (mg/dL) 14.8 
(13.7-16.3) 
14.5 
(13.0-15.5) 
n.s 15.1 
(13.6-16.3) 
13.0 
(14.4-15.5) 
n.s 14.6 
(14.1-16.7) 
14.6 
(13.6-15.6) 
n.s 
WBC (10-9/L) 5.8 
(5.1-6.9) 
5.8 
(4.9-6.9) 
n.s 5.5 
(4.8-6.4) 
5.4 
(4.4-6.3) 
n.s 6.4 
(5.4-6.9) 
6.2 
(5.4-7.6) 
n.s 
PLT (10-9/L) 195 
(168-254) 
198 
(168-248) 
n.s 195 
(168-238) 
199 
(160-228) 
n.s 209 
(162-279) 
191 
(170-269) 
n.s 
Creatinine (mg/dL) 0.83 
(0.76-0.92) 
0.82 
(0.71-0.94) 
n.s 0.8 
(0.7-0.9) 
0.8 
(0.6-0.9) 
n.s 0.9 
(0.8-1.0) 
0.9 
(0.8-1.0) 
n.s 
AST (U/l) 23 
(16-29) 
19 
(16-33) 
n.s 23 
(15-32) 
20 
(14-34) 
n.s 22 
(15-27) 
19 
(17-31) 
n.s 
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ALT (U/l) 36 
(22-53) 
31 
(22-44) 
n.s 33 
(22-53) 
30 
(20-43) 
n.s 38 
(21-57) 
32 
(26-46) 
n.s 
Total Cholesterol (mg/dL) 196 
(163-236) 
186 
(162-215) 
0.018 190 
(157-229) 
180 
(151-214) 
0.042 217 
(174-237) 
191 
(165-232) 
n.s 
HDL-Cholesterol (mg/dL) 46 
(34-54) 
47 
(36-56) 
n.s 47 
(36-53) 
48 
(37-55) 
0.012 46 
(33-56) 
45 
(35-59) 
n.s 
LDL-Cholesterol (mg/dL) 124 
(106-155) 
108 
(93-139) 
0.002 121 
(98-151) 
103 
(88-138) 
0.025 147 
(119-164) 
121 
(106-144) 
0.031 
Triglycerides (mg/dL)b 143 
(111-201) 
131 
(93-200) 
n.s 142 
(101-222) 
112 
(80-205) 
n.s 137 
(107-210) 
165 
(121-283) 
n.s 
Glucose (mg/dL) 85 
(78-92) 
82 
(79-93) 
n.s 85 
(74-92) 
81 
(79-92) 
n.s 86 
(80-93) 
82 
(78-93) 
n.s 
Insulin (mg/dL) 11.8 
(7.9-16.5) 
13.0 
(8.0-16.9) 
n.s 10.2 
(5.8-17.0) 
13.8 
(6.6-17.2) 
n.s 13.1 
(9.9-15.2) 
10.3 
(8.6-18.8) 
n.s 
HOMA-Index 2.8 
(1.6-3.4) 
2.7 
(1.7-4.1) 
n.s 2.3 
(0.9-3.7) 
2.8 
(1.2-4.1) 
n.s 3.0 
(2.1-3.3) 
2.3 
(1.8-5.0) 
n.s 
HbA1c (%)a 5.3 
(5.1-5.8) 
5.5 
(5.3-5.6) 
0.040 5.2 
(5.0-5.7) 
5.3 
(5.1-5.6) 
n.s 5.5 
(5.3-5.9) 
5.5 
(5.5-6.0) 
n.s 
CD4+ T-cells/µL 577 
(407-726) 
559 
(445-715) 
n.s 485 
(365-686) 
557 
(365-684) 
n.s 642 
(527-740) 
587 
(481-796) 
n.s 
 97 
CD8+ T-cells/µL 821 
(652-914) 
747 
(566-975) 
n.s 766 
(581-872) 
743 
(632-950) 
n.s 916 
(783-1349) 
747 
(561-1090) 
n.s 
VACS index 12 
(5-19) 
12 
(0-21) 
n.s 16 
(6-24) 
17 
(3-22) 
n.s 9 
(0-12) 
10 
(0-18) 
n.s 
Table 10. Phyisical fitness, body composition and laboratory values at baseline (BL) and week-12 (W12). Values are expressed as 1 
median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test. HR, heart rate; [La-], 2 
difference in lactate blood concentration between before and after 6MWT; ∆ RPE, difference in Rate of Perceived Exertion between 3 
before and after 6MWT; BMI, body mass index; DEXA, Dual-energy X-ray absorptiometry; HOMA, Homeostasis Model Assessment; 4 
VACS, Veterans Ageing Cohort Study. 5 
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 Women (n=9)   Men (n=12) 
 BL W12 p  BL W12 p  
        
Body composition        
Anthropometry 
       
Weight (kg) 65 
(54-79) 
62 
(53-76) 
n.s  77 
(69-82) 
72 
(63-81) 
0.00
4 
BMI (kg/m2) 24.7 
(21.5-28.7) 
24.0 
(21.3-28.5) 
n.s  25.3 
(21.6-27.5) 
24.9 
(21.2-27.0) 
n.s 
Waist circumference 
(cm) 
93.0 
(82.0-106.0) 
98.0 
(80.0-100.0) 
n.s  93.0 
(82.5-102.5) 
92.0 
(84.0-99.0) 
n.s 
Hip circumference (cm) 100.0 
(90.0-110) 
100.0 
(90.0-107.0) 
n.s  97.0 
(94.0-98.0) 
95.0 
(90.0-98.0) 
n.s 
Leg circumference (cm) 54.0 
(48.0-59.0) 
55.0 
(47.0-56.0) 
n.s  53.0 
(44.0-55.0) 
51.5 
(48.3-53.8) 
n.s 
Ultrasonography 
       
Superficial fat (mm) 29.0 
(16.0-36.5) 
24.5 
(14.3-37) 
n.s  17.5 
(12.0-19.9) 
18.7 
(12.0-30.5) 
n.s 
Visceral fat (mm) 59.0 
(37.0-68.5) 
52.5 
(36.8-69.0) 
n.s  59.0 
(51.0-99.0) 
65.0 
(44.5-74.0) 
n.s 
Total Fat (mm) 83.0 
(60.0-100.5) 
76.0 
(53.0-106.3) 
n.s  84.0 
(70.0-118.0) 
85.0 
(68.5-101.5) 
n.s 
DEXA        
Arm Fat (kg) 3.1 
(1.3-3.9) 
2.4 
(1.1-3.3) 
n.s  1.7 
(0.6-2.5) 
1.7 
(0.4-2.5) 
n.s 
Arm Fat  (%) a 38.5 
(22.2-48.7) 
38.7 
(22.7-48.5) 
n.s  20.0 
(8.1-29.0) 
20.1 
(8.7-30.6) 
n.s 
Leg Fat (kg) 5.6 
(3.1-9.8) 
7.9 
(2.9-10.4) 
n.s  2.9 
(2.1-4.1) 
2.5 
(1.0-4.1) 
n.s 
Leg Fat (%) a 24.5 
(16.8-39.9) 
21.2 
(14.5-39.8) 
n.s  14.4 
(9.8-21.2) 
17.5 
(7.4-27.7) 
n.s 
Trunk Fat (kg) 15.4 
(6.4-19.6) 
12.1 
(7.8-17.2) 
n.s  13.3 
(4.6-15.9) 
14.2 
(4.1-15.9) 
n.s 
Trunk Fat (%) 35.1 
(26.7-49.8) 
38.2 
(28.0-42.1) 
n.s  26.8 
(14.2-37.2) 
27.3 
(14.5-40.0) 
n.s 
 99 
Tot Fat (kg) 27.8 
(11.4-34.9) 
22.9 
(12.7-32.1) 
n.s  18.6 
(9.3-22.3) 
20.8 
(5.8-21.9) 
n.s 
Tot Fat (%) a 39.7 
(26.9-48.1) 
36.0 
(26.3-46.0) 
n.s  23.6 
(13.1-30.4) 
25.3 
(11.0-31.1) 
n.s 
Trunk-to-limb % fat 
ratio 
1.3 
(1.1-1.8) 
1.5 
(1.1-2.1) 
n.s  1.7 
(1.4-2.0) 
1.6 
(1.0-2.3) 
n.s 
Laboratory exams        
Haemoblobin (mg/dL) a 13.1 
(11.9-14.2) 
13.0 
(12.0-14.0) 
n.s  16.2 
(14.9-16.4) 
15.1 
(14.2-15.9) 
n.s 
WBC (10-9/L) 5.1 
(4.6-8.1) 
5.3 
(4.4-7.0) 
n.s  5.6 
(5.1-5.9) 
5.5 
(4.3-6.3) 
n.s 
PLT (10-9/L) 215 
(169-294) 
195 
(174-271) 
n.s  188 
(155-230) 
200 
(125-220) 
n.s 
Creatinine (mg/dL) a  0.67 
(0.64-0.77) 
0.65 
(0.58-0.69) 
n.s  0.84 
(0.78-0.92) 
0.81 
(0.75-0.94) 
n.s 
AST (U/l) 20.0 
(9.0-22.0) 
19.0 
(12.5-31.0) 
n.s  29.0 
(18.0-51.0) 
22.0 
(14.0-37.0) 
n.s 
ALT (U/l) 25.0 
(18.0-36.0) 
23.0 
(16.0-36.0) 
n.s  47.0 
(22.0-66.0) 
42.0 
(26.0-70.0) 
n.s 
Total Cholesterol 
(mg/dL) 
180 
(156-287) 
197 
(155-239) 
n.s  196 
(155-227) 
180 
(150-201) 
n.s 
HDL (mg/dL)  51 
(41-72) 
55 
(44-63) 
n.s  37 
(32-51) 
37 
(31-48) 
n.s 
LDL (mg/dL) 112 
(88-158) 
94 
(92-191) 
n.s  119 
(94-149) 
104 
(78-128) 
0.04
5 
Triglycerides (mg/dL)  95 
(59-210) 
102 
(73-114) 
n.s  158 
(123-258) 
148 
(87-260) 
n.s 
Glucose (mg/dL) 81 
(71-92) 
79 
(75-89) 
n.s  85 
(78-97) 
88 
(80-93) 
n.s 
Insulin (mg/dL) 8.1 
(5.8-16.2) 
13.6 
(5.6-23.0) 
n.s  13.8 
(5.4-17.4) 
14.3 
(7.2-16.7) 
n.s 
HOMA index 1.6 
(1.0-3.9) 
2.8 
(1.0-4.6) 
n.s  2.8 
(0.8-3.8) 
2.9 
(1.5-3.9) 
n.s 
HbA1c (%) 5.1 
(5.2-5.9) 
5.3 
(5.3-5.6) 
n.s  5.1 
(5.0-5.6) 
5.4 
(5.0-5.6) 
n.s 
CD4+ T cells/µL a 646 
(428-898) 
566 
(426-855) 
n.s  435 
(335-570) 
548 
(315-630) 
n.s 
CD8+ T cells/µL 698 
(550-862) 
842 
(674-1005) 
n.s  776 
(615-893) 
696 
(502-884) 
n.s 
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VACS  15 
(10-28) 
21 
(11-22) 
n.s  16 
(6-18) 
16 
(0-18) 
n.s 
Table 11. Body composition and laboratory values at baseline (BL) and week-12 (W12) in 1 
the walk group divided by gender. 2 
Values as expressed as median (Q1-Q3). W12 values were compared to BL values by the 3 
Wilcoxon matched-pairs signed rank test. 4 
a. At BL, women had higher % of fat in the arm (p=0.015), leg (p=0.034) and as total 5 
(p=0.017), lower haemoglobin (p=0.002) and creatinine levels (p=0.008), and higher CD4 6 
cell counts (p=0.009)(Mann-Whitney test). 7 
BMI, body mass index; DEXA, Dual-energy X-ray absorptiometry; HOMA, Homeostasis 8 
Model Assessment; VACS, Veterans Ageing Cohort Study. 9 
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All (n=25) 
  
Walk (n=17) 
  
Strength-Walk (n=8) 
 BL W12 p   BL W12 p   BL W12 p 
            
Total Cholesterol (mg/dL) 202 (178-235) 
193 
(173-214) 0.003  
190 
(157-229) 
180 
(151-214) 0.042  
234 
(202-236) 
194 
(191-232) 0.010 
HDL-C (mg/dL) 47 (36-55) 
48 
(39-56) 0.016  
47 
(36-53) 
48 
(37-55) 0.012  
49.0 
(41.8-60.5) 
53.0 
(46.0-64.0) n.s 
LDL-C (mg/dL) 147 (110-161) 
121 
(93-146) 0.002  
121 
(98-151) 
103 
(88-138) 0.025  
156 
(147-172) 
144 
(121-150) 0.002 
            
Table 12. Values of cholesterol at baseline (BL) and week-12 (W12) in patients untreated with statins. Values are expressed as 1 
median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test. 2 
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Discussion 
This pilot study explored the efficacy of three days per week, 12-week program of brisk 
walking, with or without strength exercise, on metabolic and inflammatory markers in 
sedentary cART-treated persons with metabolic complications. We observed, in parallel 
with improvement of physical fitness and of some morphometric measures, substantial 
improvements of cholesterol profiles and inflammatory markers. Many of the changes were 
observed in both training groups and, within the walk group, most changes did not differ 
substantially between women and men. 
From a clinical standpoint, a remarkable observation was the general reduction of total 
cholesterol, the reduction of LDL cholesterol in both training groups, and the increase of 
HDL among statin-untreated participants. Total, HDL and LDL cholesterol are each 
independent strong predictors of CVD in the general population and elevated LDL is the 
primary target for cholesterol-lowering therapy (Stone et al., 2014). In HIV-infected 
persons, higher total and lower HDL cholesterol were independently associated with CVD 
(Friis-Møller et al., 2010). While high intensity aerobic exercise is followed by favourable 
cholesterol alterations, the influence of moderate intensity aerobic and of resistance 
training is not clearly evidence-supported (Tambalis et al., 2009). 
Only a few studies have examined the effects of exercise on blood lipids in HIV infection, 
with inconsistent outcomes, likely resulting from large variability of populations and 
exercise interventions (Fillipas et al., 2010; O’Brien et al., 2010; Lindegaard et al., 2008). 
Our findings, indicating that moderate exercise may reduce blood cholesterol in HIV 
infection, support exercise interventions prior to use of cholesterol lowering drugs (Stone 
et al., 2014). 
In contrast, we observed no improvement in glucose or insulin level. Functional tests in the 
general population and HIV-positive patients showed that exercise improves insulin 
resistance, but often without changes of glucose, insulin or glycate haemoglobin level 
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(Lindegaard et al., 2008). It is thus possible that, at the exercise intensity of this protocol, 
blood static markers did not accurately reflect exercise-induced benefit on glucose control. 
Because the HRmean during the training session was set in the so-called fat-burning 
zone, the observed weight reductions were not unexpected. However, BMI and waist 
circumference reductions were less marked in the strength-walk group, likely resulting 
from increase of muscle mass, and thus of total weight, following strength exercise. In 
addition, there was no significant change in body fat by DEXA or ultrasounds examination. 
Since we prescribed no specific diet, the limited effect of exercise on body fat might reflect 
an unbalanced caloric intake following exercise. It is also possible that 12 weeks of brisk 
walking was not sufficient to reduce visceral fat, similar to what observed in obese subjects 
with type-2 diabetes or dyslipidaemia, likely resulting from a reduced capacity of fat 
oxidation (Ohkawara et al., 2007; Kelley et al., 1994). Remarkably, also HIV-negative 
patients with different chronic conditions experienced favourable and consistent effects of 
exercise on metabolic or inflammatory markers, primarily hsCRP, despite no effect on 
weight loss (Beavers et al., 2010). 
cART-controlled chronic HIV infection is associated with increased inflammation and 
coagulation (Neuhaus et al., 2011; Lederman et al. 2013; Deeks et al., 2013), and higher 
plasma levels of hsCRP, IL-6 and D-dimer strongly predicted higher overall mortality and 
cardiovascular events (Kuller et al., 2008; Duprez et al., 2012). Beyond cART, a number of 
interventions are in use, e.g., statins, or proposed, to treat inflammation (Klatt et al., 2013). 
However, the anti-inflammatory effect of exercise in HIV infection has been rarely 
addressed in clinical studies. Reductions of hsCRP, IL-6, TNF- and IL-18 were observed 
in a 16-week study of aerobic or resistance training performed at variable intensity 
(Lindegaard et al., 2008), but no of IL-6 after 6 weeks of aerobic plus resistance moderate 
intensity exercise (Dudgeon et a., 2012). Our study showed substantial reductions of 
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hsCRP, IL-6, D-dimer, IL-18 and myostatin following 12-weeks of moderate intensity 
exercise. 
In HIV-negative subjects, longitudinal studies have demonstrated exercise-induced 
changes of plasma inflammatory markers. These have largely focused on hsCRP and IL-6, 
showing more marked reductions in subjects with higher baseline levels, but no or low 
effect in healthy persons (Beavers et al., 2010; Nimmo et al., 2013). A small number of 
studies of old healthy and diabetic subjects have shown plasma reductions of IL-18, a 
cytokine released by adipocytes among other cell types (Kohut et al., 2006; Kadoglou et 
al., 2006), whereas myostatin expression in muscle tissue was found to be reduced in 
obese elderly following aerobic exercise (Ryan et al., 2013). No information is available on 
the effect of exercise on D-dimer levels, although levels of other coagulation markers have 
improved following exercise (Lockard et al., 2007). Our findings extend previous 
observations on the effect of exercise on plasma hsCRP, IL-6 and IL-18 to patients with 
HIV infection and following moderate exercise. In addition, we disclose a beneficial effect 
of exercise on plasma D-dimer and myostatin, a myokine secreted by the muscle during 
exercise. Myostatin may represent a homeostasis marker in HIV infection, because its 
inhibition increases muscle mass and, according to recent studies, also bone mass, while 
reducing fat tissue (Buehring et al., 2013). In contrast to the above markers, we did not 
observe changes of sCD14, a microbial translocation marker and independent predictor of 
mortality in chronic HIV infection (Sandler et al., 2011). Similarly, plasma levels of 
lipopolysaccharide (LPS) were not reduced by 16 weeks of endurance or strength 
interventions (Trøseid et al., 2014). Thus, effects on microbial translocation seem unlikely 
to mediate exercise-induced inflammatory alterations. 
The frequency of CD8+/CD38+/HLA-DR+ activated T-cells decreased significantly 
following exercise in both training groups. The effect of physical exercise on T-cell 
activation is unknown, with no change shown by one study in HLA-DR expression on 
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CD3+ or CD8+ T-cells in HIV-negative elderly following exercise [34]. Unlike soluble 
markers, CD8+ T-cell activation is considered a poor predictor of mortality in treated HIV 
infection (Hunt et al., 2014). Recently, higher proportions of CD8+/CD38+ cells have been 
reported in patients with visceral fat accumulation (Guaraldi et al., 2013) and of both CD4+ 
and CD8+ CD38+/HLA-DR+ cells in women with subclinical carotid artery disease (Kaplan 
et al., 2001). However the predictive value of T-cell activation in non-AIDS comorbidities 
remains controversial (Tenorio et al., 2014). Our findings suggest that decreased T-cell 
activation may contribute to mediate exercise-induced health benefit, although the clinical 
significance of these observations remains to be established. 
The interpretation of the effect of different exercise programs on inflammatory markers 
was limited by the small sample size of training groups. For the same reason, comparison 
of inflammatory changes between women and men within the walk group was not 
possible. Of note, however, reductions of hsCRP and CD8+/CD38+/HLA-DR+ cells were 
observed in both training groups, likely reflecting high sensitivity of these markers to 
exercise. Although we could not well dissect the effects of aerobic versus strength 
exercise, we observed that IL-6 and D-dimer did not improve in the strength-walk group. 
Similarly, a program of strength exercise alone did not improve plasma hsCRP or IL-6 in a 
previous study of HIV-infected subjects (Lindegaard et al., 2008). It is thus possible that 
resistance and aerobic exercise affect inflammation in different ways (Beavers et al., 2010, 
Lindegaard et al., 2008). We also observed a selective reduction of myostatin in the 
strength walk participants, which may either suggests a specific effect of strength exercise 
on myostatin expression, or reflect the greater total exercise load in this training group. 
Two main mechanisms have been suggested to mediate the effect of exercise on 
inflammation in the general population. First, the reduction of fat mass following physical 
activity may promote an anti-inflammatory environment via reduced infiltration of immune 
cells in the adipose tissue and release of adipokines, including pro-inflammatory cytokines 
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(Van Gaal et al., 2006). In addition, contracting skeletal muscle secretes molecules with 
immune modulatory effects, including the so-called myokines, most notably IL-6, which 
mediates metabolic changes during exercise. While single bouts of exercise induce an 
increase of IL-6 and other cytokines, regular exercise with repeated bouts may induce an 
anti-inflammatory environment, with lower basal levels of inflammatory markers over time 
(Lederman et al., 2013). Compared to the general population, inflammation in HIV 
infection may be caused or enhanced by specific conditions, including persisting low-level 
HIV replication, chronic co-infections, and ART induced altered lipid and metabolic profiles 
(Nimmo et al., 2013), suggesting that additional mechanisms may mediate and perhaps 
enhance the effects of exercise on inflammation. 
This study has some limitations. First, we did not include a non-exercise control group. 
However, there were no changes of medications, including lipid-lowering drugs, in the 
weeks before or during the training period, which may have affected study outcomes. 
Second, assignment to either training protocol was not randomized, but subject's own 
decision, because groups exercised in different places at different day times. While this 
favoured recruitment of participants, it resulted in an unbalanced women distribution 
between training groups. Also, the relatively small sample size of subgroups, and 
consequent low statistical power, did not allow drawing firm conclusions on efficacy of 
different exercise programs. Finally, dietary intake was not restricted, which also might 
have affected study outcomes. In conclusion, brisk walking was associated with significant 
improvement of soluble and cell inflammatory markers and cholesterol profile in sedentary 
patients with HIV infection and metabolic problems. This pilot study provides potentially 
relevant information for the design of larger controlled studies of moderate physical 
exercise as treatment of HIV-related chronic immune activation.  
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